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Abbreviations 
 
ACD-A acid citrate dextrose solution A 
ALDH aldehyde dehydrogenase 
APC antigen presenting cells 
APC allophycocyanin 
APS ammonium peroxodisulfate 
BHQ black hole quencher 
Bp, kb base pair(s); kilo base pairs  
BRCA breast cancer susceptibility protein 
BSA  bovine serum albumin 
CD cluster of differentiation 
cDNA complementary DNA 
Da dalton 
DAPI  4', 6-diamidino-2-phenylindole 
DC dendritic cells 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
ECL enhanced chemiluminescence  
EDTA Ethylenediaminetetraacetic acid 
FAM 6-FAM phosphoramidite 
FCS fetal calf serum 
FFPE formalin-fixed, paraffin-embedded 
FIGO International Federation of Gynaecology and Obstetrics 
FITC fluorescein isothiocyanate 
GM-CSF granulocyte-macrophage colony-stimulating factor 
H&E stain hematoxylin and eosin stain 
hAB human serum from blood group AB donor 
HER2 human epidermal growth factor receptor 2 
HLA human leukocyte antigen 
HRP horseradish peroxidase 
IDO indoleamine-2,3-dioxygenase 
IF immunofluorescence 
IFN interferon 
IHC immunohistochemistry 
IL interleukin 
ILT immunoglobulin-like transcript 
ITIM immunoreceptor tyrosine-based inhibitory motif 
KIR killer cell immunoglobulin-like receptor  
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Lck Lymphocyte-specific protein tyrosine kinase 
LILR leukocyte immunoglobulin-like receptor 
LN lymph node 
LPS lipopolysaccharide 
MHC major histocompatibility complex 
mRNA messenger RNA 
NK cell natural killer cell 
Nll nodi lymphatici (lymph nodes) 
PBL peripheral blood lymphocyte 
PBMC peripheral blood mononuclear cells 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin 
PFA Paraformaldehyde 
PHA phytohaemagglutinin (here phytohaemagglutinin L or leucoagglutinin)  
RB1 retinoblastoma protein  
rh rekombinant human 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute, developed RPMI1640 medium 
scHLA-G5 single-chain HLA-G5 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sHLA-G soluble HLA-G 
SN supernatant 
TAMRA carboxytetramethylrhodamine 
TMA tissue microarray 
Treg regulatory T cell 
WB Western Blot 
β2m β2-microglobulin 
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Zusammenfassung 
Einleitung  
HLA-G, ein nicht-klassisches HLA bzw. MHC Klasse Ib Molekül, kann sowohl als 
membrangebundenes als auch als lösliches Molekül verschiedenste 
Immunzellpopulationen effektiv inhibieren. Unter physiologischen Bedingungen wird 
HLA-G vor allem in der Plazenta exprimiert, wo es dazu beiträgt den semiallogenen 
Embryo vor einer Abstoßung durch das mütterliche Immunsystem zu beschützen. 
Außerdem wird HLA-G in einer Vielzahl von Tumoren wie zum Beispiel in 
Ovarialkarzinomen überexprimiert. Ziel dieser Arbeit war es besonders die Rolle von 
löslichem HLA-G im Ovarialkarzinom und die Expression von HLA-G in verschiedenen 
Subtypen des Ovarialkarzinoms genauer zu untersuchen.  
Ergebnisse 
Anhand eines Tissue Microarrays wurde bestätigt dass HLA-G unter physiologischen 
Bedingungen nur in sehr wenigen Geweben wie Plazenta oder Testes exprimiert wird. 
Außerdem wurden erstmals auch im Nebennierenmark hohe Expressionslevel detektiert. 
Im Gegensatz zur physiologischen Expression wurde HLA-G in serösen, muzinösen, 
endometrioiden und Klarzellkarzinomen und somit in Tumoren aller untersuchten 
Subtypen des Ovarialkarzinoms detektiert. Am häufigsten war HLA-G in hochgradigen 
serösen Karzinomen überexprimiert. Hier konnte gezeigt werden dass auf 
Genexpressionslevel in Ovarialkarzinomen die Expression des immunsuppressiven HLA-
G mit der Expression von klassischen MHC Molekülen wie HLA-A, -B oder -C 
hochsignifikant korreliert. Außerdem konnte in Aszitesproben von Patientinnen mit 
Ovarialkarzinomen hohe Konzentrationen von löslichem HLA-G nachgewiesen werden. 
Auch auf metastasierten Tumorzellen in regionalen Lymphknoten war HLA-G 
nachweisbar. Überraschenderweise wurde aber besonders viel HLA-G auf Dendritischen 
Zellen in Lymphknoten detektiert. Da in Monozyten und Dendritischen Zellen von 
gesunden Spendern durch IL-4 oder IL-10 im Gegensatz zu Literatur keine Expression 
von HLA-G induzierbar war, untersuchten wir ob Dendritische Zellen lösliches HLA-G 
binden. Es konnte gezeigt werden, dass besonders Dendritische Zellen die in Gegenwart 
von IL-4, IL-10 und GM-CSF aus Monozyten generiert wurden (DC-10) effektiv 
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lösliches HLA-G über ILT Rezeptoren binden. In Abhängigkeit von ihrer Beladung mit 
HLA-G hemmen auch fixierte DC-10 Zellen noch die Proliferation von zytotoxischen 
CD8+ T Zellen. Zudem wurden regulatorische T Zellen induziert.  
Schlussfolgerungen 
Besonders in den am häufigsten diagnostizierten hochgradigen serösen 
Ovarialkarzinomen ist HLA-G in den meisten Fällen überexprimiert. Durch die 
Expression immunsuppressiver MHC Klasse Ib Moleküle wie HLA-G können 
wahrscheinlich auch Tumore wachsen, die noch klassische MHC Moleküle exprimieren 
und aufgrund ihrer Mutationslast eigentlich vom Immunsystem erkannt und eliminiert 
werden müssten. Lösliches HLA-G könnte zudem lokal Immunantworten gegen 
Tumorantigene unterdrücken indem es an Dendritische Zellen in regionalen 
Lymphknoten bindet. Diese Zellen präsentieren nomalerweise zytotoxischen T Zellen 
Tumorantigene und spielen daher eine entscheidende Rolle in der Entstehung von 
protektiven Immunantworten. Mit löslichem HLA-G beladene Dendritische Zellen 
hemmen jedoch die Proliferation von CD8+ T Zellen und induzieren regulatorische T 
Zellen. Dadurch könnten Ovarialkarzinome “aus der Ferne” auch in metastasenfreien 
Lymphknoten die Entstehung von gegen den Tumor gerichteten Immunantworten 
unterdrücken. Dieser erstmals beschriebene Mechanismus könnte auch in anderen 
malignen Erkrankungen eine Rolle spielen, da lösliches HLA-G in einer Vielzahl von 
Tumorindikationen nachgewiesen wurde. 
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Abstract 
Background 
HLA-G is a non-classical MHC class I molecule which exerts strong immunosuppressive 
effects on various immune cells. Several membrane-bound and soluble isoforms are 
known. Physiologically, HLA-G is predominantly expressed in the placenta, where it 
contributes to protecting the semi-allogeneic embryo from rejection by the maternal 
immune system. However, HLA-G is also often upregulated during tumourigenesis, such 
as in ovarian cancer. The aim of this thesis is to investigate how soluble HLA-G may 
contribute to local immunosuppression in ovarian carcinomas, and to characterize HLA-
G expression in different ovarian carcinoma subtypes and metastases.  
Results 
As reported by others, physiological HLA-G expression is restricted to few tissues, such 
as placenta and testes. Here, HLA-G was also detected in the medulla of the adrenal 
gland. In contrast, HLA-G expression was frequently detected in tumours of all assessed 
subtypes of ovarian carcinomas (serous, mucinous, endometrioid and clear cell). Highest 
expression levels were detected in high-grade serous carcinomas. In primary tumours, 
expression of HLA-G correlated with expression of classical MHC class I molecules 
HLA-A, -B and -C.  Surprisingly, high levels of HLA-G were also detected on dendritic 
cells in local lymph nodes. As no expression of HLA-G was inducible in monocytes or 
dendritic cells from healthy donors in response to IL-10 or IL-4, we speculated that 
tumour-derived soluble HLA-G might be transferred to dendritic cells via the lymphatic 
system. Accordingly, high levels of tumour-derived soluble HLA-G were detected in 
ovarian cancer ascites samples. In vitro, dendritic cells expanded in the presence of IL-4, 
IL-10 and GM-CSF (DC-10) were particularly prone to binding high amounts of soluble 
HLA-G via ILT receptors. Furthermore, HLA-G loaded DC-10 cells inhibited the 
proliferation of CD8 effector cells and induced regulatory T cells, even when the DC-10 
cells had been fixed with paraformaldehyde. 
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Conclusion 
The immunosuppressive molecule HLA-G is overexpressed in high-grade serous ovarian 
carcinomas, which account for the majority of ovarian cancers. In particular tumours with 
a high mutational burden and intact expression of classical, immunogenic MHC class Ia 
molecules may use HLA-G to escape from immunosurveillance. Additionally, tumour-
derived soluble HLA-G may inhibit adaptive immune responses by binding to dendritic 
cells in local lymph nodes. Dendritic cells usually play a decisive role in the initiation of 
adaptive anti-tumour immune responses by presenting tumour antigens to cytotoxic T 
cells. In contrast, dendritic cells loaded with soluble HLA-G inhibit the proliferation of 
effector T cells and promote the induction of regulatory T cells. Thus, soluble HLA-G 
that is transferred to dendritic cells via lymphatic vessels may enable ovarian carcinomas 
to remotely suppress anti-tumour immune responses in local lymph nodes. This novel 
immune-escape mechanism may also exist in other solid tumours that express HLA-G. 
1 Introduction 
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1 Introduction 
1.1 Ovarian cancer 
1.1.1 Epidemiology, staging and risk factors 
220 000 women are diagnosed with ovarian cancer each year, and although treatment 
methods are continuously improving, 60% of these patients will die from the malignancy 
(Jayson et al. 2014). In the US, ovarian cancer is the most common cancer of the 
reproductive tract and the fifth most common cause of cancer related deaths in women 
(CDC cancer statistics 1999-2011, www.cdc.gov/uscs). This equals to a lifetime risk of 
about 1.7% in more developed nations (Jemal et al. 2011). The median age at diagnosis is 
63 (Jayson, Kohn et al. 2014). It has been shown that the use of oral contraception and 
pregnancies reduce the risk for developing ovarian cancer, possibly due to a reduced 
number of ovulations (Tsilidis et al. 2011). Factors that increase the risk for some ovarian 
cancer subtypes include obesity, menopausal hormone therapy (Yang et al. 2012), 
smoking (Collaborative Group on Epidemiological Studies of Ovarian et al. 2012) and 
hereditary risk factors such as BRCA mutations (Miki et al. 1994, Wooster et al. 1995). 
Ovarian cancer is most often staged by the FIGO (International Federation of 
Gynaecology and Obstetrics) system (Shepherd 1989). Here, spreading of the primary 
tumour (T) and metastases in lymph nodes (N) and distant organs (M) are taken into 
account. Briefly, stage I tumours are confined to the ovaries or fallopian tubes, stage II 
tumours have metastasized within the pelvis, stage III tumours have metastasized to 
retroperitoneal or extra-pelvic areas and stage IV tumours have metastasized to extra 
peritoneal organs, such as lungs, spleen or liver (Prat and Oncology 2014). Historically, 
well differentiated, moderately differentiated, poorly differentiated or undifferentiated 
ovarian carcinomas were graded from G1 to G4, respectively (Shepherd 1989). More 
recently, the World Health Organisation has adopted an alternative classification for 
ovarian carcinomas. Accordingly, ovarian carcinomas are classified either as low-grade, 
less aggressive type I and high grade, more aggressive type II tumours based on 
morphological markers and commonly detected mutations (Shih Ie and Kurman 2004). 
This system may be particularly useful for predicting the response to chemotherapeutic 
agents (Silverberg 2000). 
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1.1.2 Histopathological subtypes 
About 90% of ovarian cancers in woman age 20 or older are classified as 
adenocarcinomas or surface-epithelial-stromal tumours (Ries 2007). Other ovarian 
cancers include undefined carcinomas or sex cord-stromal tumours, mullerian tumours 
and germ cell tumours. Due to the high prevalence of adenocarcinomas, this thesis 
focuses on these subtypes.  
Most ovarian carcinomas are serous ovarian carcinomas, accounting for about 75% (70% 
high-grade, 5% low grade) of all cases (Prat 2012). About 10% each are diagnosed as 
endometrioid or clear cell carcinomas (Prat 2012), the latter being almost exclusively 
high-grade tumours (Tan and Kaye 2007). Mucinous tumours account for about 3% of 
ovarian carcinomas and are more frequently confined to the ovaries, however, usually 
less chemosensitive (Harrison et al. 2008, Prat 2012). Examples of H&E stained ovarian 
carcinoma subtypes are shown in Figure 1, a graphical overview of common ovarian 
carcinoma subtypes, frequencies and associated mutations is given in Figure 2. 
 
 
    
 
Figure 1: H&E stained serous, mucinous and clear cell ovarian carcinomas 
Micrographs of haematoxylin and eosin stained formalin-fixed, paraffin-embedded (FFPE) sections of 
serous (left), mucinous (centre) and clear cell (right) ovarian carcinomas (copyright © 2011 „Nephron“, 
published under GNU creative commons licence). 
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1.1.3 Molecular pathogenesis 
Low grade serous, mucinous and clear cell ovarian carcinomas may develop in a step-
wise manner from benign to borderline to malignant ovarian cysts (Kurman 2013). Here, 
genes such as BRAF, KRAS and ERBB2 (also known as HER2/neu) that code for proteins 
involved in signalling pathways are frequently mutated or amplified (Vang et al. 2009). 
In comparison to high grade ovarian carcinomas, these tumours are genetically more 
stable (Kurman 2013). High-grade ovarian carcinomas are thought to originate from the 
fallopian tube (Lee et al. 2007, Shaw et al. 2009). In most of these genetically less stable 
tumours, mutations in the tumour suppressor gene TP53 are detectable, and mutations in 
BRCA1 or 2 or RB1 genes are also mostly found in this subtype (Banerjee and Kaye 
2013, Kurman 2013). Further genes frequently mutated in different ovarian cancer 
subtypes are listed in Figure 2. 
 
 
 
Figure 2: Common subtypes of ovarian carcinomas and associated genetic alterations   
About 90% of all ovarian cancers are carcinomas. Among these, serous carcinomas are the most common 
subtype, followed by endometrioid, clear cell and mucinous carcinomas. As depicted, different genetic 
alterations typically occur in histologically different subtypes or low-grade and high-grade tumours (%* = 
percentage of ovarian carcinomas, not all ovarian cancers, frequencies slightly vary depending on source, 
adapted from (Banerjee and Kaye 2013), frequencies from (Prat 2012)). 
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1.1.4 Diagnosis and treatment 
If detected at early stages, ovarian carcinomas are mostly curable (Jayson, Kohn et al. 
2014). However, due to a lack of specific early symptoms, ovarian cancer has been 
termed the “silent” or “whispering” disease (Goff 2012, Smith 2006). Thus, most patients 
are only diagnosed in late stages of tumour development (mostly FIGO stage III) (Jayson, 
Kohn et al. 2014, Prat and Oncology 2015). Even yearly screening programs based on 
ultrasound and measuring serum concentrations of the tumour marker CA-125 have failed 
to reduce ovarian cancer associated mortality (Buys et al. 2011). Instead, it was found 
that such screening (Partridge et al. 2009) gives rise to numerous unnecessary surgical 
interventions and should not be recommended (Clarke-Pearson 2009). In addition to 
distant metastases, most primary serous high-grade tumours already have a diameter of 
more than 15 cm when ovarian cancer is diagnosed (Levy and Purcell 2013).  
Irrespective of the tumour subtype, ovarian carcinomas are usually treated surgically, 
with chemotherapeutics, in some cases with radiotherapy (Jayson, Kohn et al. 2014) and 
with anti-VEGF antibodies. Usually, the ovaries, fallopian tubes, the uterus, the omentum 
majus and as much of the detectable tumour mass as possible are surgically removed 
(debulking) (Eisenkop et al. 1998, King et al. 2003). First line chemotherapy for 
advanced tumours most commonly consists of DNA-crosslinking platinum-based 
chemotherapeutics (carboplatin or cisplatin) in combination with taxanes (paclitaxel or 
docetaxel) that disrupt microtubule formation (Jayson, Kohn et al. 2014). Radiation 
therapy has only been proven to be effective for certain subtypes of low-grade ovarian 
cancer (Hoskins et al. 2012) as well as for palliative treatment of metastases (Rodriguez 
et al. 1992). More recent clinical studies have shown that anti-VEGF antibodies 
(Bevacizumab) can prolong progression free survival for a few months (Aghajanian et al. 
2012, Garcia and Singh 2013, Perren et al. 2011, Pujade-Lauraine et al. 2014). 
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1.2  Ovarian cancer and immune escape 
1.2.1 Mechanisms of tumour suppression 
Like any other cancer, ovarian carcinomas are caused by accumulating genetic alterations 
that promote cell growth and survival and prevent cell cycle arrest or the induction of 
apoptosis. It has been estimated that more than one million molecular lesions occur in 
each cell every day (Lodish H et al. 2004). Most of these are instantly repaired or not 
affecting the malignant potential of a cell. However, if several decisive pathways and 
intracellular control mechanisms (or hallmarks of cancer (Hanahan and Weinberg 2000)) 
are altered within one cell, this cell may finally initiate a tumour.  
However, these control mechanisms are not limited to intracellular proteins and 
pathways. As included in a recent update to the hallmarks of cancer (Hanahan and 
Weinberg 2011), cancer cells must also escape from immunosurveillance. This concept 
was first systematically introduced by Burnet in the 70s of the last century (Burnet 1970). 
It has become evident that the innate immune system can be seen as a first line of defence 
against malignant cells, which initiates adaptive immune responses (Diefenbach and 
Raulet 2002) that in most cases contain malignant cells in microscopic lesions for a 
lifetime. Such oncogenic stress can induce the upregulation of innate natural killer (NK) 
cell receptors (Raulet and Guerra 2009). Furthermore, non-silent mutations that 
accumulate in protein-coding regions lead to the emergence of novel tumour-specific 
peptides that are presented to adaptive T cells via major histocompatibility complex 
(MHC) molecules (Diefenbach and Raulet 2002, Schumacher and Schreiber 2015, Sensi 
and Anichini 2006).  
1.2.2 Tumour immune escape 
Many researchers have addressed the question why these sophisticated control 
mechanisms sometimes fail to prevent tumours from growing into organ-sized masses as 
frequently observed particular in ovarian cancer. Here, it has been shown that cancer cells 
may adapt in an evolutionary manner to immunological assaults. This involves two key 
processes: the upregulation of immunosuppressive molecules (immunosubversion) and 
1 Introduction 
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the loss of immunogenic targets on tumour cells (immunoediting) (reviewed by Zitvogel 
et al. 2006). These processes have been integrated into a model that nicely correlates with 
clinical observations and describes three phases of tumour immune escape: elimination, 
equilibrium, and escape. Briefly, it proposes that malignant cells that are not detected and 
destroyed by the innate or adaptive immune system in the elimination phase may still be 
contained in equilibrium over prolonged periods of time. During this time, they may 
accumulate further mutations that may finally enable them to escape from 
immunosurveillance (Dunn et al. 2002, Dunn et al. 2004, Mittal et al. 2014).  
The existence of tumour latency has also been demonstrated in a mouse study where low 
doses of carcinogens usually induced a small number of stable malignant cells, that only 
started growing into clinically detectable tumours when T cells were depleted (Koebel et 
al. 2007). These microtumours may be contained by similar processes as during tumour 
dormancy, the period spanning the depletion of all clinically detectable tumour masses 
and recurrence, which can also last for decades. (Aguirre-Ghiso 2007). However, this 
model does not satisfyingly explain why malignant cells that can be constrained by the 
immune system are not immediately eliminated, or why cells that are not eliminated 
during the equilibrium do not immediately grow into overt tumours.  
1.2.3 Cancer stem cells in tumour immune escape 
We have suggested that the equilibrium phase may be maintained by immune-privileged, 
yet niche-restricted premalignant cancer stem cells (Bruttel and Wischhusen 2014). In 
ovarian cancer, different markers including CD133 (Baba et al. 2009), ALDH1 (Landen 
et al. 2010) and CD44 (Zhang et al. 2008) have been associated with the cancer stem cell 
phenotype. Stem cells are usually rare, exceptionally long-lived and highly resistant 
towards chemotherapeutic agents and have thus long been suspected to be the culprits of 
tumour development or recurrence (reviewed by Lobo et al. 2007, Reya et al. 2001). 
However, at least physiological stem cells are constrained to defined niches (Li and 
Neaves 2006). Additionally, stem cells and cancer stem cells possess unique 
immunological properties, which may explain why cancer stem cells may not be 
immunologically eliminated during the early phases of tumourigenesis (Bruttel and 
Wischhusen 2014). Thus, as depicted in Figure 3, cancer stem cells may play a decisive 
role in tumour development and immune escape in ovarian carcinomas. 
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Figure 3: Cellular and molecular processes in tumour immune escape 
Tissue homeostasis in normal epithelium. During organogenesis or in response to tissue damage, rare stem 
cells are activated to undergo asymmetric divisions that produce more differentiated progenitor cells. 
Progenitor cells regenerate tissue through symmetric cell divisions. The resulting daughter cells further 
differentiate and acquire organ-specific functions while their ability to re-enter the cell cycle is gradually 
lost. When healthy cells acquire mutations, malignant transformation can occur as a multi-step process that 
can be divided into different phases: 
Elimination. Malignant mutations occurring in somatic cells or progenitor cells are likely to be detected by 
the immune system due to oncogenic stress-induced ligands for activator NK cell receptors and tumour 
antigen presentation via MHC class Ia. These cells are subsequently eliminated, resulting in the restoration 
of normal epithelium. However, mutated cells may in some cases escape from immunosurveillance by de-
differentiating into less immunogenic stem cells. 
Equilibrium. If an oncogenic mutation occurs in an immune-evasive stem cell, this cell may not be 
eliminated by the immune system due to its low expression of immunostimulatory and high expression of 
immunosuppressive molecules. However, such premalignant stem cells may not immediately grow into 
overt tumours as they cycle slowly, depend on stem cell niches and naturally undergo only asymmetric 
divisions. Their more immunogenic daughter cells, however, may constantly be eliminated by the adaptive 
immune system. Over decades, such mutated stem cells can accumulate further genetic alterations. Thus, 
novel tumour-specific antigens may emerge, which can be taken up and presented by APCs to induce 
activation and expansion of tumour-specific T cells. This would lead to antigen spreading which 
strengthens tumour immunosurveillance and stabilizes the equilibrium. 
Escape. Immune escape mutations occurring in CSCs or premalignant daughter cells may finally lead to 
tumour outgrowth. Particular risks may be associated with genetic alterations leading to the loss of 
immune-activatory molecules (like MHC molecules or NK cell receptor ligands), or to loss of 
immunogenic tumour antigens or to the upregulation of immunosuppressive factors. Furthermore, 
immunosenescence or therapeutically induced immunosuppression may limit immunosurveillance and thus 
enable more immunogenic tumours to grow. Alternatively, poorly immunogenic CSCs may lose their niche 
dependence and expand to form poorly differentiated tumours. (Figure and Figure legend: (Bruttel and 
Wischhusen 2014)). 
1 Introduction 
 
 
    20 
1.2.4 Immune escape mechanisms in ovarian cancer 
Numerous immune escape mechanisms have been reported to occur in ovarian cancer. 
Ovarian cancer derived macrophage migration inhibitory factor (MIF), for example, 
induces the downregulation of activatory NK cell receptors (Krockenberger et al. 2008). 
Furthermore, immunosuppressive cytokines TGF-β and IL-10 are frequently detected in 
the tumour microenvironment (Loercher et al. 1999, Zitvogel, Tesniere et al. 2006). 
Prostaglandin E2 not only inhibits immune effector cells such as macrophages (Harris et 
al. 2002), but may also promote metastasis (Spinella et al. 2004). Vascular endothelial 
growth factor (VEGF) may not only promote vascularisation, but also suppress immune 
effector cells (Kandalaft et al. 2011). Furthermore, ovarian carcinoma cells express the 
immunosuppressive surface molecules CD200 (Siva et al. 2008) and indoleamine-2,3-
dioxygenase (IDO), which arrests T cell proliferation (Qian et al. 2009). The 
ectonucleotidases CD39 and CD73 that generate immunosuppressive adenosine are also 
overexpressed in ovarian cancer (Hausler et al. 2011). Classical human leukocyte 
antigens (HLA) class Ia molecules or proteins of the antigen processing machinery are 
often not detectable in late stage ovarian carcinomas, which correlates with a poor 
prognosis (Han et al. 2008, Vitale et al. 2005). In contrast, the immunosuppressive, 
nonclassical MHC Ib molecule HLA-G is frequently expressed in ovarian cancer (Sheu 
and Shih Ie 2007). The important role of HLA-G in ovarian carcinoma will subsequently 
be discussed in detail. 
Combined, these effects generate an immunosuppressive tumour microenvironment that 
locally promotes immunological tolerance towards ovarian cancer cells (Yigit et al. 
2010). Accordingly, immunosuppressive regulatory T cells are frequently detected in 
late-stage ovarian cancers (Woo et al. 2001), and myeloid derived suppressor cells (Yigit, 
Massuger et al. 2010) are associated with an unfavourable clinical outcome. On the other 
hand, tumour-infiltrating CD8+ effector T cells (Sato et al. 2005) and dendritic cells 
(Eisenthal et al. 2001) are indicators of a good prognosis. Immunosuppressive molecules 
expressed by ovarian cancer cells as well as affected immune cells are also shown in 
Figure 4. 
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Figure 4: Immune escape mechanisms in ovarian cancer and affected immune cells 
Immunosuppressive molecules secreted by or expressed on the surface of ovarian carcinoma cells (red cell, 
centre) and intratumoral immune cell subpopulations that are affected by these molecules are shown. See 
main text for references. 
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1.3 HLA-G 
1.3.1 MHC molecules 
HLA-G is a non-classical major histocompatibility complex (MHC) class Ib molecule. In 
humans, genes coding for antigen-presenting molecules such as HLA-A, -B, -C, -E, 
-F and -G are clustered in the MHC class I region, while genes coding for HLA-DP, 
HLA-DQ and HLA-DR belong the MHC class II region. The MHC class III complex 
genes code for cytokines, heat shock proteins and components of the complement system 
(Horton et al. 2004). More recently, it was suggested that this complex could be 
subdivided in class III and IV genes (Gruen and Weissman 2001). All human MHC genes 
are located in an approximately 3.6 mega base, gene-dense region on chromosome 6 
(6p21.31) (Horton, Wilming et al. 2004, MHC sequencing consortium 1999). 
MHC class II molecules consist of an alpha and a beta chain with each 2 extracellular 
domains of which α1 and β1 form the peptide-binding cleft. MHC class II molecules are 
mostly expressed on antigen presenting cells and present linear peptides of 15 to 24 
amino acids that are derived from phagocytosed proteins. MHC class II proteins have a 
high affinity for CD4 that is expressed on T helper and regulatory T cells. 
MHC class Ia molecules HLA-A, -B and -C are expressed on almost all nucleated cells. 
They comprise an alpha chain with three extracellular domains that is non-covalently 
linked to a beta2-microglobulin. The peptide-binding groove is made up from the α1 and 
α2 domain. The presented peptides are 8 to 10 amino acids long and contain defined 
anchor residues that stabilize the peptide within the cleft. These peptides are usually 
derived from intracellular proteins (MHC peptide presentation has been comprehensively 
reviewed by Neefjes et al. 2011). The α3 domain and beta2-microglobulin bind CD8. 
Thus, CD8+ cytotoxic T cells that express T cell receptors recognizing pathogenic 
peptides can detect and eliminate malignant or virally infected cells. MHC class Ia and 
class II molecules are highly polymorphic. Thus, within a population, a huge variety of 
peptides can be immunologically detected, which reduces the risk that non-detectable 
pathogens rapidly spread through a population. Interestingly, it has been shown that 
MHC phenotypes influence body odour, and that animals and humans may preferentially 
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select mates with divergent MHC subsets, which would enable the offspring to react to a 
greater variety of pathogens (Consuegra and Garcia de Leaniz 2008, O'Dwyer and Nevitt 
2009).  
1.3.2 MHC class Ib molecules 
In contrast to MHC class Ia molecules, non-classical MHC class 1b molecules HLA-E, -F 
and -G display very low polymorphism, particularly in the peptide-binding domains. 
They structurally resemble MHC Ia molecules, bind β2-microglobulins and HLA-G 
and -E present peptides (Bhutta 2007, Chaix et al. 2008). They do, however, have a 
shortened cytoplasmic segment (O'Callaghan and Bell 1998, Rodgers and Cook 2005). 
As discussed in detail below, HLA-E and -G inhibit NK cell and T cell functions, while 
the precise role of HLA-F is still unclear. It has recently been shown that HLA-F does not 
present peptides but interacts with inhibitory receptors on NK cells (Goodridge et al. 
2013). Additionally, MHC class Ib molecules have a very restricted expression pattern. 
The physiological and pathological relevance of MHC Ib molecules will be discussed on 
the example of HLA-G, which has first been described by Gerathy et al. in 1987 as HLA-
6.0 (Geraghty et al. 1987). 
1.3.3 Physiological expression of HLA-G 
Physiologically, highest levels of HLA-G are expressed during embryonic development. 
It was first detected on cytotrophoblast cells within the placenta (Geraghty, Koller et al. 
1987), but later studies revealed that it is already expressed in fertilized oocytes and 
detectable in cleavage-stage embryos and blastocysts (McMaster et al. 1995). 
Furthermore, HLA-G is detectable in spermatogenic testicular tissues and seminal plasma 
(Verloes et al. 2011, Yao et al. 2014). The immunosuppressive effects on both the 
adaptive and innate immune system (see 1.3.5) and the expression on the feto-maternal 
interface suggest that HLA-G may play an important role in protecting the semi-
allogeneic embryo from the maternal immune system (Dahl et al. 2014, Yao, Shu et al. 
2014). The finding that embryos originating from assisted reproduction techniques that 
secrete more soluble HLA-G (sHLA-G) have a significantly increased chance to lead to 
successful pregnancies after transplantation supports this view (Rizzo et al. 2011).  
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HLA-G has also been detected in the thymus (Rebmann et al. 2010), specifically on 
medullary thymic epithelial cells (Crisa et al. 1997) which play a decisive role during 
central tolerance induction (Mallet et al. 1999). Furthermore, HLA-G is expressed in the 
immune-privileged cornea (Passos et al. 2015) and in pancreatic islets (Le Discorde et al. 
2003). 
1.3.4 Immune cell receptors interacting with HLA-G  
The immunosuppressive effects of HLA-G are mediated via various receptors expressed 
on immune cells. Best characterized are interactions with immunoglobulin-like transcript 
(ILT) receptors 2 and 4 and the killer-cell immunoglobulin-type receptor KIR2DL4 
(Cirulli et al. 2006). Furthermore, CD160, which is expressed by endothelial cells, may 
also interact with HLA-G (Fons et al. 2006).  
ILT receptors have also been referred to as leukocyte Ig-like receptors (LIR), HM/HL 
transcripts or monocyte/macrophage Ig-like receptors (MIR) (Allan et al. 2000). ILT2 
(CD85j) and ILT4 (CD85d) possess 4 extracellular Ig domains (Allan, McMichael et al. 
2000), of which the first two interact with the α3 domain of MHC class I molecules and 
beta2-microglobulin (Clements et al. 2005), or, in the case of ILT4, also with beta2-
microglobulin-free HLA-G (Gonen-Gross et al. 2005). Here, ILT2 and 4 compete with 
CD8 for the same MHC class I structures, but while CD8 has a higher affinity for MHC 
Ia molecules, ILT2 and 4 preferentially bind HLA-G (Shiroishi et al. 2003). CD8 
promotes T cell activation through the associated lymphocyte-specific protein tyrosine 
kinase (Lck) (Artyomov et al. 2010, Barber et al. 1989, Delon et al. 1998). In contrast, 
ILT 2 and 4 inhibit immune cells via several immunoreceptor tyrosine-based inhibitory 
motif (ITIM)-related sequences (Allan, McMichael et al. 2000). While ILT4 is only 
expressed on myeloid cells such as monocytes, macrophages and dendritic cells, (Allan, 
McMichael et al. 2000, Colonna et al. 1998), ILT2 is also expressed on lymphoid 
lineages such as T cells, NK cells and B cells (Allan, McMichael et al. 2000, Colonna et 
al. 1997, Cosman et al. 1997).    
KIR2DL4 (CD185d) also contains only one intracellular ITIM (Yusa et al. 2002) and its 
only known ligand is HLA-G (Rajagopalan and Long 1999). It is expressed on some 
CD8+ T cells all NK cells (Rajagopalan and Long 1999) while highest levels are detected 
on CD56bright NK cells (Goodridge et al. 2003). CD56bright NK cells most frequently occur 
1 Introduction 
 
 
    25 
in the uterus (Cooper et al. 2001). Some reports suggest an inhibitory function for this 
receptor (Goodridge, Witt et al. 2003, Yusa, Catina et al. 2002), others suggest that it 
may activate NK cells which could promote angiogenesis during early pregnancy 
(Rajagopalan and Long 2012). A recent report even suggested that effects of HLA-G on 
KIR2DL4 may be indirect and due to contaminations (Le Page et al. 2014). 
HLA-G has also been reported to upregulate the expression of ILT2, 3 and 4 and 
KIR2DL4 in immune cells (Braud et al. 1999). 
1.3.5 HLA-G mediated immunosuppressive effects  
By activating these receptors HLA-G inhibits various immune effector cells. Effects of 
HLA-G on different immune cell subsets have been comprehensively reviewed by 
Carosella et al. (Carosella et al. 2008) and are displayed in Table 1. 
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Table 1: Direct HLA-G mediated effects on immune effector cells 
Immune cell subset / effect of HLA-G Receptors involved 
CD8+ T cells 
Inhibition of cytotoxic function unknown 
Inhibition of proliferation ILT2 
Generation of CD8low regulatory T cells unknown 
Apoptosis CD8 
CD4+ T cells 
Inhibition of alloreactivity ILT2, ILT4 
Inhibition of proliferation ILT2 
Up-regulation of inhibitory receptors unknown 
Generation of regulatory T cells, which include CD4low T cells unknown 
NK cells 
Inhibition of cytotoxic function ILT2, KIR2DL4 
Inhibition of proliferation ILT2 
Up-regulation of inhibitory receptors unknown 
Apoptosis CD8 
Increased proliferation and IFNγ production KIR2DL4 
Increased secretion of pro-angiogenic factors Internalized KIR2DL4 
Inhibition of trans-endothelial migration ILT2 
Inhibition of cytotoxic function ILT2, KIR2DL4 
APC 
Inhibition of DC maturation, antigen presentation, trafficking, and induction of 
regulatory T cells ILT4 
Up-regulation of inhibitory receptors unknown 
Adapted from (Carosella, Favier et al. 2008), all references see (Carosella, Favier et al. 2008). 
 
1.3.5 Structure and isoforms of HLA-G 
The HLA-G gene comprises 8 exons und 7 introns, of which exons 1 to 6 code for the 
mature protein. Exon 1 codes for the 5’ untranslated region and the leader peptide. 
Exon 2, 3 and 4 code for the α1, α2 and α3 domains, respectively. Exon 5 codes for the 
transmembrane domain and exon 6 for a short intracellular tail and the stop codon. 
Alternative splicing processes can lead to 7 different isoforms of HLA-G. Membrane-
1 Introduction 
 
 
    27 
bound HLA-G2, 3 and 4 isoforms lack the α2 and/or α3 domain due to exon skipping 
during transcription. Soluble isoforms emerge due to intron retention of intron 2 
(HLA-G7) or intron 4 (HLA-G5 and 6), which contain alternative stop codons (Carosella, 
Favier et al. 2008, Carosella et al. 2003). Alternatively, soluble isoforms such as shed 
HLA-G1 (sHLA-G1) (Moreau et al. 1995) can result from proteolytic cleavage of 
membrane-bound isoforms through matrix metalloproteinases (MMP) such as MMP-2 
(Rizzo et al. 2013). All known isoforms of HLA-G are displayed in Figure 5. 
 
 
 
 
   HLA-G1         -G2         -G3        -G4        sHLA-G1     HLA-G5       -G6       -G7 
                membrane-bound             soluble 
 
Figure 5: Structure of the HLA-G gene and HLA-G isoforms 
The HLA-G gene comprises 6 protein-coding exons (E1-E6, I = intron). Alternative splicing yields 7 
distinct protein isoforms, of which HLA-G1-4 are membrane-bound and HLA-G5-7 are soluble. Proteolytic 
cleavage of all membrane-bound HLA-G isoforms through MMP2 may also generate soluble HLA-G. 
Exons and corresponding domains are displayed in matching colours. Figure adapted from (Carosella, 
Favier et al. 2008, Carosella, Moreau et al. 2003). 
 
Dimers of HLA-G which result from disulphide bonds involving cysteine residues at 
positions 42 and 147 may be particularly effective in activating HLA-G receptors 
(Shiroishi et al. 2006). These have been detected both in soluble (Juch et al. 2005) and 
membrane-bound forms (Boyson et al. 2002).   
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1.3.6 Transfer of HLA-G 
As discussed, the physiological expression of HLA-G is restricted to a few tissues. 
However, matters are complicated by mechanisms which transfer HLA-G proteins from 
one cell to another.  
One mechanism that has been studied in detail is trogocytosis (reviewed by Davis 2007, 
Joly and Hudrisier 2003). Upon cell-cell contact, both T or NK cells temporarily acquire 
cell membrane patches from APC or tumour cells which include membrane-bound 
HLA-G. This alters effector cells to become transiently tolerant (Caumartin et al. 2007, 
LeMaoult et al. 2007).  
Another mechanism of HLA-G transfer is via exosomes. Exosomes are extracellular 
vesicles of 50-90 nm in diameter in which surface proteins have the same orientation as 
in a cell and that enclose small amounts of cytoplasm. They are generated in larger, 
intracellular multivesicular bodies, which fuse with the cell membrane in order to release 
exosomes (reviewed by Fevrier and Raposo 2004). Exosomes bearing HLA-G molecules 
have been detected in tumour cell line supernatants as well as in pleural exudates and 
ascites from cancer patients (Alegre et al. 2013, Riteau et al. 2003).  
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1.4 Role of HLA-G in ovarian carcinoma 
1.4.1 HLA-G expression in malignant diseases  
HLA-G expression has been detected in a large variety of malignancies. Interestingly, the 
frequencies at which HLA-G positive tumours are detected within investigated entities 
vary from 0% (uveal melanoma) to 100% (hydratiform moles, which originate from the 
placenta) (reviewed by Amiot et al. 2011). HLA-G expression has also been detected in 
some of the most frequent malignancies including breast cancer, lung cancer, colorectal 
cancer, prostate cancer and melanoma (comprehensively reviewed by Carosella et al. 
2008, Rouas-Freiss et al. 2005).  
The choriocarcinoma cell line Jeg-3 stably expresses HLA-G (Burt et al. 1991). 
However, other cell lines generated from primary tumour cells that initially express HLA-
G lose expression when cultured over prolonged periods of time (Rouas-Freiss et al. 
2005). This may explain why, in some entities, it is difficult to study the relevance of 
HLA-G expression for tumourigenesis in vitro. Nevertheless, some initially negative 
tumour cell lines upregulate HLA-G when treated with inflammatory cytokines like 
tumour necrosis factor alpha (TNF-α) or interferon gamma (IFN-γ) (Wiendl et al. 2002). 
1.4.2 HLA-G expression in ovarian carcinoma 
HLA-G has been detected in about 60 to 70% of high-grade serous carcinomas but only 
rarely in low-grade serous carcinomas (Menier et al. 2009, Singer et al. 2003). Soluble 
HLA-G was detected in 25 of 25 high-grade serous ascites samples (Singer, Rebmann et 
al. 2003). This clearly indicates that HLA-G and particularly soluble HLA-G may play a 
role in ovarian cancer progression.  
This is further supported by findings showing that HLA-G expression in primary ovarian 
cancer cells protects these cells from NK cell mediated lysis (Lin et al. 2013, Lin et al. 
2007). Besides, HLA-G expression may induce matrix metalloproteinases and thus 
increase tumour invasiveness and metastases formation (Lin, Xu et al. 2013). The 
relevance of HLA-G in tumour progression has also been demonstrated by 
overexpressing HLA-G in ovarian cancer cell lines. Nude mice inoculated with HLA-G 
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transfected ovarian cancer cell lines suffered from more widespread metastases and 
survived significantly shorter as compared to mice inoculated with parental cells (Lin et 
al. 2012).  
HLA-G has been suggested as a biomarker for ovarian carcinomas (Menier, Prevot et al. 
2009). HLA-G expression may also predict susceptibility towards certain 
chemotherapeutic agents (Davidson et al. 2005). 
Jung et al. found that HLA-G expression in high and low grade carcinomas correlates 
with disease progression and inversely correlates with patient survival (Jung et al. 2009). 
In contrast, a tissue microarray (TMA) based study in which only high-grade tumours 
were analysed showed that elevated expression of HLA-G correlated with improved 
patient survival (Rutten et al. 2014).  
1.4.3 Induction of HLA-G in ovarian carcinoma 
The HLA-G gene is physiologically silenced in epithelial and other tissues due to 
hypermethylation of CpG sites (Mouillot et al. 2005). Thus, these tumours must undergo 
cis-acting epigenetic changes in order to express HLA-G. Correspondingly, methylation 
patterns in the 5’ region of the HLA-G gene were significantly different in malignant 
ovarian carcinoma cells as compared to benign or normal ovarian surface epithelium 
(Menendez et al. 2008). However, HLA-G transcription may also be enabled by 
demethylating agents which have been used in ovarian cancer trials (Brown et al. 2014).  
The transcriptional regulation of the HLA-G gene is unique even among MHC class Ib 
molecules (Gobin and van den Elsen 2000). Numerous environmental factors have been 
shown to induce or increase the expression of HLA-G in tissues or tumours in which the 
HLA-G gene is accessible. These include hypoxia (Mouillot et al. 2007), stress, cytokines 
such as GM-CSF, IL-10, interferons and leukaemia inhibitory factor (Bamberger et al. 
2000), hormones such as progesterone (Ivanova-Todorova et al. 2009) or glucocorticoids 
(Moreau et al. 2001) (reviewed by Carosella, Moreau et al. 2003).  
Elevated concentrations of IL-10 have also been detected both in serum and ascites of 
ovarian cancer patients (Gotlieb et al. 1992, Mustea et al. 2006). Furthermore, some 
ovarian cancer cell lines secrete IL-10 (Berger et al. 2001). High levels of IL-10 
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frequently correlate with HLA-G expression in different tumour entities (Urosevic and 
Dummer 2003). 
Interestingly, IL-10 in combination with IL-4 and GM-CSF has been reported to induce 
dendritic cells which express HLA-G and induce tolerogenic T cells (Gregori et al. 2010). 
During pregnancy, IL-4 may also induce the expression of HLA-G5 in T cells 
(Lombardelli et al. 2013).  
1.5 Aims of this thesis  
While expression of HLA-G has been well documented in high-grade serous ovarian 
carcinoma cells, HLA-G expression in clear cell, mucinous or endometrioid ovarian 
carcinomas has only been investigated in one study with 2, 5 and 6 samples, respectively 
(Menier, Prevot et al. 2009). Therefore, one aim of this thesis was to investigate the 
frequency of HLA-G expression in these ovarian carcinoma subtypes.  
As discussed, HLA-G is a potent immunosuppressive molecule and may thus promote 
tumour growth. However, in high-grade carcinomas, its expression correlates with a 
favourable clinical outcome (Rutten, Dijk et al. 2014). Interestingly, Gajewski et al. have 
suggested that two immunological groups of solid tumours may exist. One subset of 
tumours is infiltrated by immune cells, but actively suppresses them. In contrast, 
immune-ignorant or immunoedited tumours may emerge because cancer cells stop 
expressing immunogenic proteins (Gajewski et al. 2013). If this is the case in ovarian 
carcinomas, immunosubversive tumours that express MHC Ib molecules such as HLA-G 
could grow despite expressing classical MHC Ia molecules. In contrast, HLA-G negative 
tumours should have evolved alternative immune-escape mechanisms including 
downregulation of classical MHC molecules. In order to test if these distinct immune 
escape strategies may be observable in ovarian carcinomas, published gene-expression 
datasets from ovarian carcinomas were screened for mRNAs expressed in correlation 
with HLA-G mRNA. 
Furthermore, we set out to investigate whether tumour-derived cytokines may induce the 
expression of HLA-G in immune cells in primary lesions or regional lymph nodes.  
Finally, the relevance of soluble HLA-G during tumourigenesis in this malignancy should 
be further elucidated. As discussed, ovarian carcinomas frequently accumulate numerous 
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mutations (Hunt et al. 2006) and grow into large solid tumours without causing specific 
symptoms. Here, membrane-bound HLA-G may clearly help to suppress immune effector 
cells infiltrating the tumour. In contrast, soluble HLA-G should be constantly transported 
out of the tumour microenvironment via the lymph and then diluted and distributed via 
circulation throughout the body. Thus, it is unclear how soluble HLA-G may contribute 
to regional immunosuppression. It has been shown that soluble HLA-G induces apoptosis 
in T and NK cells (Contini et al. 2003, Lindaman et al. 2006, Pistoia et al. 2007). 
However, if this occurs on a systemic rather than local level, patients should experience 
severe immune-related symptoms including opportunistic infections. These are not 
typically observed during “silent” ovarian tumourigenesis. Thus, it remains unclear how 
soluble HLA-G may promote local tumour immune escape.  
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2 Material and methods 
2.1 Material 
If not directly indicated, company locations are listed in Supplements,  
Table 6 
2.1.1 Software 
Use Software & Manufacturer 
Confocal image acquisition ImagePro Plus, Leica, Germany 
Data handling Microsoft Excel 2010 & 2011,  Microsoft Cooperation 
ELISA data analysis Magellan, Tecan Trading AG 
Figure compilation  Corel Draw X4, Corel Corporation 
Flow Cytometry Attune cytometry software v2.1.0,  Thermo Fisher Scientific Inc. 
Gene expression analysis R2 genomics analysis and visualization platform (www.r2.amc.nl) 
Graphs & charts GraphPad Prism 6, GraphPad Software, Inc. 
Image and blot analysis ImageJ, Wayne Rasband (NIH) 
Image handling Photoshop CS3, Adobe Systems Inc. 
Real-time PCR analysis 7500 Software, Applied Biosystems Inc. 
Statistical analysis GraphPad Prism 6, GraphPad Software, Inc. 
TaqMan design Primer3, http://primer3.ut.ee/ 
Text editor Microsoft Word 2010 & 2011,  Microsoft Cooperation 
Citation manager EndNote X4, Thompson Reuters  
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2.1.2 Important devices 
Device Model & Manufacturer 
Absorbance reader Sunrise, Tecan Trading AG 
Agarose gel electrophoresis apparatus MupidexU, Eurogentec GmbH, Cologne, Germany 
Autoclave H P Labortechnik AG, Oberschleißheim, Germany 
Centrifuges 
5810 R, 5424 R: Eppendorf, Hamburg, Germany 
Jouan C4i, Heraus Megafuge 16: Thermo Electron GmbH, 
Dreieich, Germany 
CO2 incubator Thermo Electron GmbH 
Confocal microscope laser-scanning microscope TCS SP5 II, Leica 
Digital camera Canon, USA 
Electronic balance Sartorius AG, Göttingen, Germany  
Flow cytometer Attune Flow Cytometer, Thermo Fisher Scientific Inc. 
Freezers  (-20°C, -86°C) 
Liebherr, Germany;  
Thermo Electron GmbH 
Philipp Kirsch GmbH, Offenburg, Germany 
Inverted microscope  Leica, Solms, Germany 
Laminar flow hood Heraeus, Hanau, Germany 
Photometer Thermo Electron GmbH  
Real-Time PCR cycler 7500Fast Real-Time PCR System, Applied Biosystems 
Western blotting system Mini-Protean® Tetra Cell, Bio-Rad Laboratories, Inc. 
2.1.3 Consumables 
Consumable Specification & Manufacturer 
96-well PCR plate ABITaqMan-Plate, Fisher Scientific GmbH 
Cell culture flasks (25, 75 or 150 cm2)  TPP Techno Plastic Products AG 
Cell culture plates  
(6, 12, 24 or 96 well flat or round bottom) TPP Techno Plastic Products AG 
ELISA plates  Nunc (Maxisorp), Roskilde, Denmark  
Falcon tubes (15 ml, 50 ml) Greiner Bio One International GmbH 
Fixer & developer  Eastman Kodak  
LS magnetic columns Miltenyi Biotec GmbH 
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Consumable Specification & Manufacturer 
Lumox dishes, 35 mm, soft bottom Sarstedt AG & Co, Nümbrecht, Germany 
Micro test tubes  Greiner Bio One International GmbH 
PVDF membrane, 0.2 µm pores Roti®-Fluoro PVDF, Carl Roth GmbH + Co. KG 
SuperFrost microscope slides & cover slips  Carl Roth GmbH + Co. KG 
TaqMan design Primer3, http://primer3.ut.ee/ 
X-ray films  Fisher Scientific GmbH  
 
2.1.4 Cells, cell lines and supernatants 
Biological material Source 
Jeg-3 choriocarcinoma cell line ATCC Manassas, VA, USA 
Peripheral blood mononuclear cells (PBMCs) Healthy blood donors 
LCL-HLA-G5B2M (scHLA-G5) supernatant 
Supernatant from LCL 721.221 cells transfected with a 
pRc-RSV vector containing human beta2-
microglobulin, a (4GS)4 linker and human HLA-G5. 
The soluble HLA-G concentration is 0.87µg/ml. Kind 
gift from Dr. Joël LeMaoult, Hôpital Saint Louis, Paris. 
LCL-RSV (ctrl) supernatant 
Supernatant from mock transfected LCL 721.221 cells 
(empty pRc-RSV vector), no HLA-G detectable. Kind 
gift from Dr. Joël LeMaoult, Hôpital Saint Louis, Paris. 
2.1.5 Tumour and ascites samples  
Sample Source 
Ascites samples 
Ascites from ovarian cancer patients was drained for 
symptoms relief by doctors of the Universitäts-
Frauenklinik Würzburg and provided for scientific 
purposes anonymized and with informed consent. 
FFPE serous ovarian carcinoma and lymph node 
sections 
FFPE tumour samples were anonymized and provided 
by the Institute of Pathology, University of Würzburg. 
All patients had signed a form indicating their informed 
consent regarding the use of surgical specimens for 
scientific purposes.  
Healthy control FFPE tissue microarray 
The CHTN Norm2 normal adult FFPE tissue 
microarray was bought from the Cooperative Human 
Tissue Network via the university of Virginia…. 
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Sample Source 
…Central nervous system tissues were obtained from 
autopsy specimens within 36 hours after death. All 
other tissues were obtained from surgical resections and 
fixed within one hour with 3.7% formaldehyde. Three 
1mm cores from each tissue were combined into a 
tissue microarray, which was sectioned on charged 
glass slides at 4 µm. For each tissue, donor age and sex 
are listed below. 
Ovarian carcinoma FFPE tissue microarray 
The CHTN OvCa1 ovarian carcinoma FFPE tissue 
microarray was also bought from the Cooperative 
Human Tissue Network. Four 0.6mm cores from each 
tumour were combined into a tissue microarray, which 
was sectioned on charged glass slides at 4 µm. Patient 
characteristics are listed in Table 2 
2.1.6 Cell culture reagents 
Reagent Manufacturer 
Phosphate-buffered saline (PBS) Sigma-Aldrich Co. LLC 
RPMI-1640 Sigma-Aldrich Co. LLC 
Penicillin (10kU/ml) and streptomycin 
(10mg/ml) (P/S) Sigma-Aldrich Co. LLC 
Sodium pyruvate (100mM) Sigma-Aldrich Co. LLC 
Human AB serum (hAB) Serum from human serotype AB donors,  PAA Laboratories, GE Healthcare  
Fetal calf serum (FCS) GE Healthcare 
Acid citrate dextrose (ACD-A) Haemonetics Corporation 
Accutase PAA Laboratories, GE Healthcare  
Biocoll separation solution Biochrom GmbH 
Trypsin EDTA PAA Laboratories, GE Healthcare  
Cell Proliferation Dye eFluor 670 eBioscience, Inc. 
Phytohemagglutinin (PHA) Biochrom GmbH 
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2.1.7 Chemicals & solution reagents 
Reagent Manufacturer 
37%-formaldehyde Sigma-Aldrich Co. LLC 
40% Acrylamide/Bis solution Bio-Rad Laboratories, Inc. 
Agarose Carl Roth GmbH + Co. KG 
Ammonium peroxodisulfate (APS) Carl Roth GmbH + Co. KG 
Aprotinin Carl Roth GmbH + Co. KG 
Bovine serum albumin (BSA) AppliChem GmbH 
Bovines Serum Albumin (BSA) AppliChem GmbH 
Bradford reagent Roti-Quant Carl Roth GmbH + Co. KG 
Bromophenol blue Carl Roth GmbH + Co. KG 
Chloroform Sigma-Aldrich Co. LLC 
Diaminobenzidine (DAB) Dako, Agilent Technologies, Inc. 
Dimethylsulfoxid (DMSO)  Carl Roth GmbH + Co. KG 
Ethylenediaminetetraacetic acid (EDTA) AppliChem GmbH 
GelRed Biotium Inc. 
Glacial acetic acid Carl Roth GmbH + Co. KG 
Glycerol Carl Roth GmbH + Co. KG 
Glycine Carl Roth GmbH + Co. KG 
Leupeptin Carl Roth GmbH + Co. KG 
Sodium chloride (NaCl) Carl Roth GmbH + Co. KG 
NP-40 AppliChem GmbH 
Phenylmethanesulfonylfluoride (PMSF)  Carl Roth GmbH + Co. KG 
Phorbol 12-myristoyl 13-acetate (PMA) Sigma-Aldrich Co. LLC 
Ponceau S Carl Roth GmbH + Co. KG 
Potassium (di) hydrogen phosphate Carl Roth GmbH + Co. KG 
Potassium chloride Carl Roth GmbH + Co. KG 
Skimmed milk powder Merck KGaA 
Sodium chloride (NaCl) Carl Roth GmbH + Co. KG 
Sodium dodecyl sulfate (SDS) Carl Roth GmbH + Co. KG 
Sodium fluoride (NaF) AppliChem GmbH 
Sodium hydroxide Carl Roth GmbH + Co. KG 
Sodium orthovanadate (NaVO5) AppliChem GmbH 
Sodium(di)hydrogen phosphate Carl Roth GmbH + Co. KG 
2 Material and methods 
 
 
    38 
Reagent Manufacturer 
Streptavidin-HRP Dako, Agilent Technologies, Inc. 
Tetramethylethylenediamine (TEMED) Carl Roth GmbH + Co. KG 
TRI Reagent (TriZol) Sigma-Aldrich Co. LLC 
Trichloroacetic acid Carl Roth GmbH + Co. KG 
Tris-HCL Carl Roth GmbH + Co. KG 
Tween20 Carl Roth GmbH + Co. KG 
Sodium acetate Carl Roth GmbH + Co. KG 
H2O2 30% Carl Roth GmbH + Co. KG 
Na2CO3 Carl Roth GmbH + Co. KG 
VitroClud Langenbrinck, Emmendingen, Germany 
β-mercaptoethanol Carl Roth GmbH + Co. KG 
2.1.8 Buffers, solutions and media 
Buffer/Solution Composition 
1 x MOPS buffer 10% 10 x MOPS buffer, 2% 37%-formaldehyde, 88% H2O 
10 x MOPS buffer 400 mM MOPS, 100 mM NaAc, 10 mM EDTA, pH 7 
50 x TAE 2 M Tris, 0.6 M EDTA, 0.57% glacial acetic acid  
Antibody Diluent Dako REAL 
Complete RPM1640 5% 
hAB serum 
93.5% RPMI 1640, 5% human AB serum, 1% P/S, 0.5% sodium pyruvate 
Complete RPMI1640 10% 
FCS 
88.5% RPMI 1640, 10% FCS, 1% P/S, 0.5% sodium pyruvate 
ELISA blocking buffer PBS, 4% BSA 
ELISA coating buffer 100 mM Na2CO3, pH9.6 
ELISA dilution buffer PBS, 1% BSA 
ELISA sodium acetate 
solution 
0.1 M sodium acetate, pH 6.0 
ELISA TMB solution TMB substrate kit, Biolegend 
ELISA washing buffer PBS, 0,.05% Tween20 
FACS buffer PBS, 2% FCS  
Fluoromount G Southern Biotech 
Freezing medium 70% FCS, 20% Complete RPMI1640 10% FCS, 10% DMSO  
Hematoxylin solution Carl Roth GmbH + Co. KG 
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Lysis buffer P H2O, 50 mM Tris-HCl, pH 8, 120 mM NaCl, 5mM EDTA, 0.5% NP-40 
MACS-Buffer PBS pH 7.2, 0.5% BSA, 2 mM EDTA  
PBS 37 mM NaCl, 2.7 mM KCl, 80 mM Na2HPO4, 1.8 M KH2PO4, pH 7.4  
TBS  10 mM Tris-HCl, 150 mM NaCl, pH 7.5  
TBS-T TBS, 0.05% Tween20  
TRIS buffer  TRIS 0.1M, pH 7.6 
WB 5x protein loading 
buffer 
100 mM Tris-HCl pH 6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol, 
10% β-mercaptoethanol 
WB blocking buffer  TBS-T, 5% skim milk powder  
WB ECL solution A 50 mg luminol in 200 ml 0.1 M Tris-HCl, pH 6.8  
WB ECL solution B 11 mg para-hydroxycoumarinic acid in 10 ml of DMSO  
WB lysis buffer Lysis buffer P, 2 µg/ml Aprotinin, 10µg/ml Leupeptin, 100 µg/ml PMSF, 50 
mM NaF, 200 µM NaVO5 
WB neutralizing buffer  1.5 M Tris-Base pH 7.4   
WB Ponceau S solution 0.2% Ponceau S in 3% trichloroacetic acid 
WB running buffer 25 mM Tris, 193 mM glycine, 0.5% SDS, pH 8.8 
WB stripping buffer 0.2 M glycine, 0.5 M NaCl, pH 2.8 
WB transfer buffer 25 mM Tris, 192 mM glycine, 20% methanol 
WB = Western Blot 
2.1.9 Cytokines 
Cytokine Manufacturer 
rhIL-2 PeproTech, Inc. 
rhIL-4 Immunotools GmbH 
rhIL-10 Miltenyi Biotec GmbH 
rhGM-CSF Immunotools GmbH 
rhTGF-β PeproTech, Inc. 
rh = recombinant human 
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2.1.10 Antibodies and labelling agents 
Antigen Clone Source/isotype Label Use Manufacturer 
Biotin Streptavidin - HRP ELISA ImmunoTools 
HLA-G Mem-G9 mouse - ELISA ExBio 
β2-microglobulin B2M-01 mouse biotin ELISA ExBio 
CD11c MJ4-27G12 mouse IgG2b FITC FC Miltenyi Biotec 
CD14 MEM-18 mouse FITC FC ImmunoTools 
CD3 BW264/56 mouse PE or FITC FC Immunotools 
CD3 BW264/56 mouse APC-Vio770 FC Miltenyi Biotec 
CD4 MEM-241 mouse IgG1 PE FC ImmunoTools 
CD56 N901 mouse IgG1 APC FC Immunotech 
CD86 IT2.2 mouse IgG2b, κ APC FC BioLegend 
CD8b SIDI8BEE mouse IgG1, κ PE-Cy7 FC eBioscience 
HLA-DR LT-DR Mouse IgG2a PE FC ImmunoTools 
HLA-G Mem-G9 mouse FITC or APC FC Life technologies 
ILT4 42D1 rat IgG2a PE FC eBioscience 
Isotype RTK2758 rat IgG2a, κ PE FC Biolegend 
Isotype MOPC-21 mouse IgG1 FITC/PE FC BioLegend 
Mouse IgG Poly4053 goat APC FC BioLegend 
Rat IgG Poly4054 goat FITC FC BioLegend 
FoxP3 PCH101 mouse APC FC eBioscience 
HLA-G 87G mouse IgG2a κ - FN BioLegend 
ILT2 HP-F1 mouse IgG1 κ - FN eBioscience 
ILT4 27D6 rat IgM - FN eBioscience 
Isotype eBM2a mouse IgG2a κ - FN eBioscience  
KIR2DL4  mAB33 mouse IgG1 κ - FN BioLegend  
Cytokeratin KL1 mouse IgG1 AF647 (Zenon) IF Beckman Coulter 
Mouse IgG H+L polyclonal donkey AF555 IF Molecular Probes 
Mouse IgG3 polyclonal goat AF488 IF Molecular Probes 
CD68 PGM1 mouse IgG3 - IF, IHC Dako 
Cytokeratin KL1 mouse IgG1 - IHC Beckman Coulter 
WT1 WT49 mouse IgG1 - IHC Leica 
Anti-mouse Ig polyclonal horse HRP WB Cell Signaling 
2 Material and methods 
 
 
    41 
Antigen Clone Source/isotype Label Use Manufacturer 
Anti-rabbit Ig polyclonal goat HRP WB Cell Signaling  
β-actin Poly6221 rabbit - WB BioLegend 
HLA-G 4H-84 mouse IgG1 - WB, IHC, IF BD Pharmingen 
Antigen: all antigens are human, Ig = Immunoglobulin, H+L = heavy and light chain 
Labels: AF = AlexaFluor, others see abbreviations, Zenon = labelled with Zenon labelling kit  
Uses: FC = flow cytometry, WB = Western Blotting, IHC = immunohistochemistry, IF = 
immunofluorescence, FN = functional/blocking 
 
2.1.11 Kits 
Reagent Manufacturer 
iScript cDNA Synthesis Kit  Bio-Rad Laboratories, Inc. 
MACS NK Cell Isolation Kit II, human Miltenyi Biotec GmbH 
MACS anti-CD14 beads, human Miltenyi Biotec GmbH 
MACS CD8+ T Cell Isolation Kit, human Miltenyi Biotec GmbH 
MACS CD4+ T Cell Isolation Kit II, human Miltenyi Biotec GmbH 
TaqMan Platinum® Quantitative PCR SuperMix-UDG Thermo Fisher 
Zenon® Mouse IgG1 Labelling Kit AlexaFluor647 Life Technologies 
ADVANCE™ HRP IHC Kit Dako, Agilent Technologies 
Foxp3 / Transcription Factor Staining Buffer Set eBioscience 
Matched IL-4 ELISA antibody pairs Immunotools 
Matched IL-10 ELISA antibody pairs Immunotools 
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2.1.12 Oligonucleotides 
The following oligonucleotides were used for HLA-G mRNA TaqMan qPCR:  
Oligonucleotide Sequence 5 ́ -> 3 ́  Source 
18s RNA, fw primer  CGGCTACCACATCCAAGGAA Eurogentec 
18s RNA, rev primer GCTGGAATTACCGCGGCT Eurogentec 
18s RNA, probe, yakima yellow 5’ TAMRA 3’ TGCTGGCACCAGACTTGCCCTC Eurogentec 
mHLA-G RNA, fw primer  CTCTCAGGCTGCAATGTGAA Sigma 
mHLA-G RNA, rev primer CATGAGGAAGAGGGTCATGG Sigma 
mHLA-G RNA, probe, FAM 5’ BHQ1 3’ TGCAGAGACCAGCCCACCCC Sigma 
sHLA-G RNA, fw primer  CCCCTCATGCTGAGTAAGGA Sigma 
sHLA-G RNA, rev primer GGTGAAGGTGAGGGTCTCTG Sigma 
sHLA-G RNA, probe, Texas Red 5’ BHQ2 3’  AGGGTCGGTGGTGAGGCTG Sigma 
 
2.1.13 Standards and ladders 
Use Ladder  Manufacturer 
Protein  Spectra Multicolor Broad Range Thermo Fisher Scientific Inc. 
RNA RiboRuler High Range Thermo Fisher Scientific Inc. 
 
2.1.14 Disinfectants  
 
Use Reagent Manufacturer 
Skin disinfection Cutasept BODE Chemie GmbH, Hamburg, Germany 
Work space disinfection 70% Ethanol Hospital pharmacy 
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2.2 Methods 
In order to improve readability, methods are listed in the same order as results whenever 
feasible. 
2.2.1 Immunofluorescence 
FFPE serous ovarian carcinoma and lymph node samples were cut into 4 µm sections 
with a microtome, mounted on charged microscope slides and dried. Sections from FFPE 
TMAs were already mounted on microscope slides.  
In order make the proteins accessible, all sections were de-waxed for 25 minutes in 
xylene and rehydrated for 5 minutes each in 100%, 90%, 80%, and 70% ethanol followed 
by 10 minutes in H2O. Antigens were retrieved by boiling for 20 minutes in a steamer in 
citrate buffer pH 7.0. Slides were then transferred into TRIS buffer. 
All following steps were carried out in a humid chamber in order to avoid evaporation. 
Unspecific binding sites were blocked with Antibody Diluent for 15 minutes. HLA-G 
was stained for 1h with anti HLA-G antibody (clone 4H-84) diluted 1:20 in Antibody 
Diluent. Slides were then washed 3 times for 5 minutes with TRIS buffer on a shaker. For 
visualization, AlexaFluor555-labeled donkey anti-mouse IgG was diluted 1:400 in 
Antibody Diluent and also incubated for 1h, followed by 3 x 5 minutes washing with 
TRIS buffer. 
Slides were then blocked for 1h with mouse serum diluted 1:20, followed by 3 more 
identical washing steps. CD68 staining was carried out for 1h with antibody clone PGM1 
diluted 1:50, followed by identical washing steps and 1h incubation with an AlexaFluor 
488 labelled goat antibody specific for mouse IgG3. This secondary antibody was diluted 
1:400. 
Meanwhile, cytokeratin staining was prepared. For each slide, 10 µl of the pan-
cytokeratin antibody KL1 were mixed with 10 µl Zenon AlexaFluor647 for 7 minutes. 
The labelling reaction was stopped with 10 µl Zenon block (7 min), and 170 µl TRIS-
buffer were added. Staining was carried out for 1h, followed by 3 washes. Slides were 
2 Material and methods 
 
 
    44 
then treated with formalin for 10 minutes, washed 3 more times, mounted with 
Flouromount G and dried at 8°C in the dark over night. 
2.2.2 Immunohistochemistry 
First steps in immunohistochemistry were carried out as described above for 
immunofluorescence. However, only one antigen was stained for on each section. WT1 
was detected with WT49 antibody. After the primary antibody had been washed off, 
slides were incubated with 0.3% H2O2 in TRIS buffer for 15 minutes. Secondary antibody 
staining was carried out using the ADVANCE™ HRP kit according the manufacturers 
protocol. Slides were then counterstained with haematoxylin solution and dehydrated 
with ascending ethanol concentrations (70%-100%). Sections were embedded in a drop 
of Vitroclud with a coverslip and sealed in nail varnish. 
2.2.3 ELISA 
ELISA was used to quantify IL-4, IL-10 and soluble HLA-G in ovarian carcinoma and 
benign ascites samples. For IL-4 and IL-10 detection, matched ELISA antibody pairs 
(Immunotools) and standards were used as described by the manufacturer. For HLA-G 
detection, MEM-G9 was used as a capture antibody (2 µg/ml) and anti-ß2-microglobulin 
antibody B2-M01 labelled with biotin (1 µg/ml) was used as detection antibody. LCL 
scHLA-G5 SN diluted in dilution buffer was used as a standard. Highest standard 
concentration was 400 ng/ml, which was diluted 5 times in 4fold dilutions (400, 100, 25, 
6.25, 1.58, 0.39 ng/ml). The following protocol was used: 
50 µl of capture antibody diluted in coating buffer was added to each well of a Nunc 
maxisorp 96-well plate which was stored in a humid box overnight at 4°C. The capture 
antibody was removed by flicking the plate over a sink and each well was washed twice 
with 200 µl washing buffer. Remaining protein-binding sites on the plate were blocked 
for 1h at room temperature in a humid box by adding 300 µl blocking buffer. Each well 
was washed two more times with washing buffer. 50 µl of standards and samples in 
appropriate dilutions were added to the wells in duplicates and incubated on the plate in a 
humid box for 2h at room temperature. The plate was then washed 4x with washing 
buffer. Then, 50 µl of detection antibody diluted in dilution buffer was added to each well 
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and incubated at room temperature in a humid box for 1h. Plates were then washed 4 
more times with washing buffer, before 50 µl streptavidin-HRP (diluted 1:250 in dilution 
buffer) were added to each well. The plate was then kept for 30 minutes in a humid at 
room temperature. After four more washes, 50 µl substrate solution (freshly prepared 5 
ml 0.1M sodium acetate pH 6.0, 50 µl TMB, 1 µl 30% H2O2) was added. Depending on 
colour development, plates were kept at room temperature or 37°C for up to 15 minutes 
before the reaction was stopped by adding 25 µl of 1M H2SO4. Absorption at 450 nm and 
at the reference wavelength 620 nm were measured with the Sunrise reader. Absorption 
values were normalized to reference values, the mean blank values (dilution buffer only) 
were subtracted and the concentrations determined by curve-fitting algorithms provided 
by the Magellan software. 
2.2.4 Cell culture 
General notes 
All steps were carried out under sterile conditions, protective containers were only 
opened under laminar flow hoods. Unless otherwise indicated, cells were always 
centrifuged at 350 x g for 5 minutes. All viable cells were maintained in incubators at 
37°C, 5% CO2 and >95% humidity. A water bath set for 37°C was used to prewarm 
media, PBS or other solutions added to the cells. Neubauer chambers were used for cell 
counting.  
Thawing of cells 
Cryopreserved cells were thawed at 37°C and immediately diluted in 15 ml PBS. Cells 
were centrifuged once to remove DMSO and the pellet was resuspended in complete 
media. Cells then used for experiments or seeded into appropriate cell culture flasks and 
cultured in an incubator. 
Culturing and subculturing 
Depending on cell densities and planned experiments, Jeg-3 cells were cultured in 
complete RPMI1640 10% FCS (see 2.1.8) in appropriate cell culture flasks and 
subcultured 2-3 times per week. For subculturing, adherent Jeg-3 cells were first washed 
with 10 ml PBS. 0.5 to 1ml of trypsin/EDTA solution was added to the flask, which was 
returned to the incubator until all cells were detached (2-5 min). Trypsin was inactivated 
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by 5 ml of Complete RPMI1640 10% FCS and the detached cells were usually split 1 to 
10 before being transferred into a new cell culture flask for further culture.  
PBMC or immune cell subsets were usually cultured in 6-, 12-, or 24-well plates in 
RPMI1640 medium supplemented with 5% human serotype AB serum, sodium pyruvate 
and antibiotics (Complete RPM1640 5% hAB serum, see 2.1.8). 
Cryopreservation of cells 
For cryopreservation, adherent cells were first detached with Trypsin/EDTA and then 
centrifuged. The cell pellet was resuspended in 1 ml of fresh freezing medium and the 
solution transferred to cryovials. These were kept in cryogenic boxes at -80°C for 24h. 
Vials were then transferred to liquid nitrogen tanks.  
2.2.5 PBMC isolation 
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood of healthy 
volunteers or leukocytes from whole-blood leukoreduction filters diluted 1:1 with sterile 
PBS. 10% acid citrate dextrose solution (ACD-A) was added to prevent clotting. 35 ml of 
such diluted blood were carefully layered over 15 ml Biocoll solution in a 50 ml-Falcon 
tube and centrifuged at 600 x g for 20 minutes without subsequent braking. PBMC within 
the “cloudy” interphase were carefully extracted, transferred to a new 50 ml-Falcon tube 
and washed twice with PBS (standard centrifugation).  
2.2.6 Isolation of immune cell subsets 
Either freshly isolated PBMCs or thawed PBMCs were used for the isolation of immune 
cell subsets. CD4+ and CD8+ T cells and NK cells were isolated using negative isolation 
kits, CD14+ cells were isolated using positive isolation kits (all Miltenyi). Subset 
isolation was done according to the manufacturers protocols using LC columns and 
appropriate magnets. Cell purities as verified by flow cytometry were usually 90 to 95%. 
In some experiments, the flow through (e.g. CD14- cells or peripheral blood lymphocytes, 
PBL) was also collected.  
In some experiments, monocytes were enriched by adherence. Briefly, PBMC in 
Complete RPMI1640 10% FCS were cultured for 1 hour on sufficiently large petri 
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dishes. Then, non-binding cells were thoroughly rinsed off by pipetting PBS onto the 
dishes. Adherent cells were then detached by trypsin/EDTA and matured into 
macrophages or dendritic cells. 
2.2.7 HLA-G induction 
HLA-G protein induction 
For Western Blotting, 2 x 106 purified cells (CD14+ monocytes or CD4+ or CD8+ T cells 
or NK cells) were used. 1 x 106 PBMCs were used for flow cytometry. Cells were 
cultured in Complete RPM1640 5% hAB serum alone or in the presence of 10 ng/ml IL-
4, 10 ng/ml IL-10 or 10 ng/ml of each cytokine for 48h. Monocytes were not analysed in 
detail in flow cytometry experiments because no HLA-G was detectable in preliminary 
experiments and monocytes were highly auto-fluorescent and unspecifically bound high 
amounts of antibodies irrespective of Fc receptor blocking strategies.  
HLA-G mRNA induction 
HLA-G mRNA induction was quantified in 5 x 105 cells per condition. Purified CD14+ 
monocytes, CD4+ and CD8+ T cells and NK cells were cultured in Complete RPM1640 
5% hAB serum alone or in the presence of 10 ng/ml IL-4 or 10 ng/ml IL-10 for 6h.  
2.2.8 Flow cytometry 
Protocol  
Flow cytometry was used in numerous experiments. Below, cell numbers, antibody 
combinations and concentrations and individual staining protocols are listed for each 
experiment. Unless indicated otherwise, cells were kept on ice or at 4°C during all steps. 
Antibodies were diluted 1:100 in FACS buffer unless indicated differently. All antibodies 
are abbreviated by the bound antigen and coupled fluorophore, all antibody details are 
listed in materials. Generally, cells were blocked with 10% hAB serum in FACS buffer 
for 30 min, stained in 100 µl in 96-well V bottom plates, washed twice with 200 µl FACS 
buffer and transferred to FACS tubes in 400 µl FACS buffer for analysis. After each step, 
cells were pelleted at 450 x g for 5 minutes at 4°C, supernatants were removed by 
flicking. Cells were analysed with the Attune®Acoustic Focusing Cytometer. The 
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specific fluorescence intensity (SFI) was calculated by dividing the mean fluorescence 
intensity of the specific antibody by the mean fluorescence intensity obtained with the 
respective isotype control antibody. 
Antibody combinations 
Purity assessment after immune cell subset isolation 
Number of cells analysed 2-5 x 104 
Combination of antibodies  CD3 APC-Vio770, CD4 PE, CD8 PE-Cy7, CD14 FITC, CD56 APC 
 
Analysis of HLA-G surface expression 
Number of cells analysed All cells used in experiment/condition 
Combination of antibodies  HLA-G (MEM-G9) FITC or isotype FITC, CD3 APC-Vio770, CD4 PE, CD8 PE-Cy7 and CD56 APC 
 
Analysis of ILT4 surface expression 
Number of cells analysed All cells used in experiment/condition 
Combination of antibodies 
(dilution)  
Primary antibody: ILT4 rat IgM or isotype rat IgM (1:50) 
Secondary antibody: anti-rat FITC (1:50) 
CD3 APC-Vio770, CD4 PE, CD8 PE-Cy7, CD56 APC 
After each step, cells were washed twice in 200 µl FACS buffer 
 
Treg staining 
Number of cells analysed All cells used in experiment/condition 
Combination of antibodies 
Monensin treatment 2mM added for 4h (for IL-10) 
Surface staining: CD4 PE, CD8 PE-Cy7 
Fixation and permeabilisation: FoxP3 staining kit 
Intracellular staining: FoxP3 APC, IL-10 AlexaFluor488  
(IL-10 staining not shown) 
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T cell proliferation staining 
Number of cells analysed All cells used in experiment/condition 
Combination of antibodies Dye eFluor
® 670 staining see 2.2.15 
CD4 PE, CD8 PE-Cy7, CD3 FITC, 7-AAD (1:100) 
 
2.2.9 Protein isolation, SDS-PAGE and Western Blotting 
Protein isolation and quantification 
Cells were washed 3x with cold PBS and lysed for 20 minutes in 50 µl lysis buffer P 
(with protease and phosphatase inhibitors, see 2.1.8) on ice. Lysates were spun at 1300 x 
g for 20 minutes to remove debris and the supernatant was transferred to new 1.5 ml 
tubes. Protein concentration was determined by the Roti®-Quant Bradford Assay 
according to the manufacturers protocol. Usually, 20 µg proteins were loaded on each 
lane. 5x loading buffer supplemented with 10% β-mercaptoethanol was added and 
proteins were denatured for 5 minutes at 95°C. Samples were then cooled down on ice, 
spun down and kept on ice until being loaded on the gel. 
Gradient gel preparation 
The Mini-Protean® Tetra Cell system was used for gel casting and Western Blotting. 
Separating gel solutions where prepared from the following reagents.  
Separating gel 15% 12.5% 10% 7.5% 
Stacking 
gel 
dd H2O 2.19 ml 2.1375 ml 2.45 ml 2.763 ml 3.7ml 
40% acrylamide mix 2.25 ml 1.5625 ml 1.25 ml 0.938 ml 0.625ml 
1.5 M Tris-HCl+SDS pH 8.8 1.56 ml 1.3 ml 1.3 ml 1.3 ml - 
0.1 M Tris-HCl+SDS pH 6.8  - - - - 0.625ml 
10% APS 30 µl 25 µl 25 µl 25 µl 50 µl 
TEMED 3 µl 2.5 µl 2.5 µl 2.5 µl 10 µl 
 
APS and TEMED were added just before layering. Each gel was layered with about 2 cm 
15% polyacrylamide gel solution followed by each about 1.3 cm 12.5%, 10% and 7.5% 
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gel solutions. Then, 150 µl of isopropanol were added to exclude bubbles. After 30 min, 
isopropanol was removed with a whatman paper. Then, the stacking gel was added and 
the comb was inserted. 
SDS Gel electrophoresis 
The casted gel was inserted into the holder and the buffer tank was filled with 1 x running 
buffer. The comb was carefully removed and samples and the protein ladder (8µl) were 
loaded. Constant 30mA per gel (maximum voltage) were applied for 1h for 
electrophoresis.  
Western blotting 
The nitrocellulose membrane was activated in methanol, washed in ddH2O and 
equilibrated in transfer buffer for 5 minutes each. Whatman papers and sponge pads were 
soaked in transfer buffer. Gel, membrane and whatman papers were stacked according to 
the Mini-Protean protocol and proteins were transferred at 100V constant for 1h.  
Detection 
The remaining protein-binding sites were blocked for 1h with 5% skimmed dry milk in 
TBS-T. The primary antibody (4h-84 mouse anti-HLA-G) was diluted 1:1000 in 5% 
skimmed dry milk in TBS-T and incubated over night at 4°C. The membrane was washed 
three times for 5 minutes with TBS-T. The polyclonal HRP-coupled secondary antibody 
was diluted 1:5000 in TBS-T containing 5% skimmed dry milk and incubated for 1h. The 
membrane was then washed three more times.  
Luminol-based developmment solution (here ECL) was prepared by mixing 1 ml ECL A, 
100 µl ECL B and 1 µl 30% H2O2. The membrane was incubate for 1 minutes in ECL 
solution and transferred to an X-ray film cassette. Luminescence was detected by X-ray 
film which was developed and fixed in the dark.  
For re-probing, membranes were stripped with stripping buffer followed by neutralization 
with neutralizing buffer (10 minutes each). Membranes were then blocked and incubated 
with anti-β-actin (1h) and corresponding secondary antibodies (1h) for normalisation as 
described above.  
X-ray films were subsequently labelled, scanned and bands were quantified with ImageJ. 
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2.2.10 RNA isolation and reverse transcription 
All immune cells treated as described in 2.2.7 were collected and washed once in PBS. 
The cell pellet was resuspended, lysed in 0.5 ml TriFast reagent and RNA was isolated 
according to the manufacturers protocol. Briefly, each sample was lysed for 15 minutes at 
room temperature. 100 µl chloroform was added followed by vigorous vortexing. 
Samples were kept for 10 minutes at room temperature before phases were separated by 
centrifugation for 10 minutes at 12000 x g. The clear phase was transferred to a new 1.5 
ml tube and RNA was precipitated at 4°C with 0.25 ml isopropanol. The RNA was 
pelleted and washed twice with 1 ml 75% ethanol (centrifugation 10 min, 12000 x g, 
4°C). Ethanol was removed and the RNA pellets air-dried at room temperature. The RNA 
was resuspended in 20 µl ddH2O.  
Quality control 
RNA concentration and quality were measured by photometry. RNA was diluted 1:100 
and absorbance was measured at 260 nm and 280 nm. The concentration was determined 
according to the following formula: 
CRNA [µg/ml] = OD260 nm x 100 (dilution factor) x 40 
Only RNA with a 260 nm/280 nm ratio >1.6 was used for further experiments. 
1µg of RNA from each sample was reversely transcribed into complementary DNA 
(cDNA) with the iScript kit according to the manufacturers protocol. cDNA was diluted 
1:10 in nuclease-free ddH2O. 
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2.2.11 mHLA-G and sHLA-G TaqMan qPCR 
Several semiquantitative protocols for detecting different isoforms of HLA-G mRNA via 
northern blotting have been described (Paul et al. 2000). Additionally, HLA-G TaqMan 
quantitative PCR (qPCR) kits are commercially available, but lack detailed information 
regarding primer and probe sequences. Thus, we developed a probe-based qPCR protocol 
that allows for quantifying membrane-bound (mHLA-G) and soluble (sHLA-G) isoforms 
separately. Primers and probe for soluble HLA-G were located on exon 4 and intron 4, 
primers and probe for membrane-bound isoforms on exon 6 and 7. Multiple alignments 
of HLA-G, HLA-A and HLA-F generated with ClustalW (standard DNA settings, 
http://www.ebi.ac.uk/Tools/msa/clustalw2/) were used to detect stretches in the mRNA 
sequence that were as HLA-G-specific as possible. Primers and probes were then 
designed using the frodo/primer3 homepage. Melting temperatures of primers and probes 
were designed to match a published 18s TaqMan primer and probe set (Mjosberg et al. 
2009). Multiple alignment and primer and probe locations for mHLA-G are shown in 
Figure 6. 
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                    Exon 6 
HLA-A AAAGGAGGGAGCTACTCTAAGGCTGAGTGGAGCGACAGTGCCCAGGGGTC 1184 
HLA-G AAAGGAGGGAGCTACTCTCAG----------------------------- 1216 
HLA-F AACAGAGGGAGCTACTCTCAGG---------------------------- 1154 
       **..**************.** 
     Exon 7 
HLA-A TGAGTCTCACAGCTTGTAAAGCCTGAGACAGCTGCCTTGTGTGCGACTGA 1234 
HLA-G  ------------------------------GCTGCAATGTG--------- 1227 
HLA-F  ----------------------------CTGCAGCCTACTCAG------- 1169 
                                  **:**.:: * 
 
HLA-A  GATGCACAGCTG--CCTTGTGTGCGACTGAGATG-CAGGATTTCCTCACG 1281 
HLA-G  ---AAACAGCTG--CCCTGTGTGGGACTGAGTGG-CAAGT---------- 1261 
HLA-F  --TGGTCAGCGGAAACTTGATGATAACATGGTGGTCAAG----------- 1206 
        . :**** *  .* **:  . .**: .*: * **.* 
 
HLA-A  CCTCCCCTATGTGTCTTAGGGGACTCTGGCTTCTCTTTTTGCAAGGGCCT 1331 
HLA-G  ----CCCTTTGTGACTTCAAGAACCCTGACTCCTCTTTGTGCAGAG---- 1303 
HLA-F  ----CTTATTTCTCCTGGGGGTGCTCTTCCAAGGATATTTGGGCTGCCTC 1252 
         *  ::*    **  ..* .* **  *:   .*:* ** .  * 
 
HLA-A  CTGAATCTGTCTGTGTCCCTGTTAGCACAATGTGAGGAGGTAGAGAAACA 1381 
HLA-G  ----------------------------------------------ACCA 1307 
HLA-F  CGGAGTCACAGTG--------------------------------TCTTG 1270 
                                               .  . 
 
HLA-A  GTCCACC--TCTGTGTCTACCATGACCCCCTTCCTCACACTG-ACCTGTG 1428 
HLA-G  GCCCACC--CCTGTGCCCACCATGACCCTCTTCCTCATGCTG-AACTGCA 1354 
HLA-F  GGCCGCCGGAAGGTGGGTGACATGTGGATCTTGTTTTTTTTGTGGCTGTG 1320 
 * **.**   . ***   ..****:  . ***  * :   ** . *** . 
 
Figure 6: Multiple HLA alignment and primer/probe locations for mHLA-G 
Multiple alignment of HLA-A, -G, and –F mRNA exons 6 and 7 (* = identical nucleotide, other symbols = 
non-identical nucleotides) as generated using ClustalW and primer and probe locations (bold) are shown.  
 
The following primers and probes were used: 
Oligonucleotide length, Tm, GC-content, location 
18s RNA, fw primer  20 bp, 62°C, 55% 
18s RNA, rev primer 18 bp, 58°C, 61.1% 
18s RNA, probe, yakima yellow 5’ TAMRA 3’ 22 bp, 72°C, 63.6% 
mHLA-G RNA, fw primer  20 bp, 60°C, 50%, Exon 6/ Exon 7 
mHLA-G RNA, rev primer 20 bp, 60°C, 60%, Exon 7 
mHLA-G RNA, probe, FAM 5’ BHQ1 3’ 20 bp, 70°C, 70%, Exon 7 
sHLA-G RNA, fw primer  20 bp, 60°C, 55%, Exon 4/Intron 4 
sHLA-G RNA, rev primer 20 bp, 60°C, 60%, Intron 4 
sHLA-G RNA, probe, Texas Red 5’ BHQ2 3’  20 bp, 70°C, 70%, Intron 4 
fw = forward, rev = revers 
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TaqMan qPCR was set up according to the Platinum Quantitative PCR SuperMix-UDG 
kit instructions. Briefly, the following reagents were combined: 
Reagent Amount per well (15 µl) Final concentration 
2x PCR SuperMix-UDG  7.5 µl 1x 
10 µM forward primer 0.3 µl 0.4 µM 
10 µM reverse primer 0.3 µl 0.4 µM 
10 µM TaqMan probe 0.15 µl 0.2 µM 
Nuclease-free ddH2O To 10 µl - 
Sample cDNA (1:10) 5 µl ~25 ng 
We have also tested whether HLA-G and 18s can be quantified within the same well (not shown). This is 
possible when high HLA-G cDNA concentrations are expected, but 18s primer concentrations should be 
reduced to 40 nM.  
 
qPCR cycling conditions 
The 7500Fast qPCR cycler was used with the following settings 
Step Temperature  Time Cycles 
UDG Incubation 
Initial denaturation 
50°C 
95°C 
2 min 
2 min 
 
Denaturation 95°C 15 sec 45 cycles 
Annealing and Elongation 60°C 30 sec  
Holding 4°C -  
 
Primer/probe efficiencies were analysed using several Jeg-3 cDNA dilutions (1:10, 1:100, 
1:1000, 1:10 000, 1:100 000). sHLA-G cDNA was only detectable in 1:10 and 1:100 
dilutions and was therefore not analysed in further experiments. mHLA-G and 18s cDNA 
quantities were detectable with the used primer/probe sets over 5 log10 scales in an almost 
linear manner (R2 = 0.987 and 0.997, respectively. See also Figure 7) 
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Figure 7: TaqMan qPCR enables the quantification of low levels of mHLA-G mRNAs 
Jeg-3 cDNA was diluted in log10 steps and mHLA-G and 18s cDNAs were quantified by TaqMan using 
the described primer/probe sets and cycling conditions. CT values plotted against log10 dilutions are shown. 
mHLA-G cDNA was detectable in 1:10-6 dilutions of Jeg-3 cDNA from 1 µg of RNA. Primer/probe 
efficiencies for each experiment were determined via the slope.   
 
Primer/probe efficiencies were calculated for each experiment using the following 
formula: 
efficiency = (10^(-1/slope)-1)·100 
These were used to correct measured CT values and then for determining mHLA-G 
cDNA concentrations in immune cell samples. 
2.2.12 Generation of DC and DC-10  
DC and DC-10 were differentiated from bead-purified monocytes from healthy donors. 5 
x 106 monocytes per ml were cultured for 7 days in Complete RPMI1640 10% FCS 
supplemented either with 10 ng/ml rhIL-4 and 50 ng/ml rhGM-CSF (DC, elsewhere also 
referred to as iDC) or 10 ng/ml rhIL-10, 10 ng/ml rhIL-4 and 50 ng/ml rhGM-CSF (DC-
10). Media was replaced on day 3 and day 5. After 7 days, cells were analysed by flow 
cytometry or used for experiments. 
y = -2,6976x + 8,0665 
R² = 0,99653 
y = -2,6535x + 23,299 
R² = 0,98659 
10 
20 
30 
40 
-7 -6 -5 -4 -3 -2 -1 
C
т 
dilution [log10] 
18s 
mHLA-G 
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2.2.13 Transfer of scHLA-G5 to DC-10 
2.5 x 105 DC-10 were washed once with PBS, and the cell pellet was resuspended in 
250 µl Complete RPMI1640 10% FCS with 10 ng/ml rhIL-10, 10 ng/ml rhIL-4 and 50 
ng/ml rhGM-CSF. Then, 250 µl LCL-scHLA-G5 or LCL-ctrl supernatant were added. 
Unless indicated otherwise, scHLA-G5 was transferred to DC-10 for 4h at 37°C with 
agitation. DC-10 were then washed 3 times with 1ml PBS and used for further 
experiments. 10µg/ml anti-HLA-G (cone 87G), anti-ILT-2 (clone HPF1) or anti-ILT-4 
(clone 27D6) blocking antibodies were added before the transfer in the experiment shown 
in 3.4.4. 
2.2.14 Induction of regulatory T cells  
1 x 106 syngeneic PBL were cultured in an incubator alone or with 5 x 105 DC-10ctrl or 5 
x 105 DC-10scHLA-G5 for 7 days in RPMI hABc with IL-2 and TGFβ1 (5ng/ml each). 
Medium was replaced every second day. FoxP3 or IL-10 expression were then analysed 
by flow cytometry as described in 2.2.8.  
2.2.15 CD8+ T cell proliferation assays 
For each setting, 4 x 105 syngeneic PBL were stained with 5 µM Cell Proliferation Dye 
eFluor670 according to the manufacturers instructions. PBL were cultured alone or with 5 
x 105 DC-10ctrl or 5 x 105 DC-10scHLA-G5 for 24h in 100 µl RPMI hABc with IL-2 (20 
ng/ml). Then, 1µg/ml PHA was added to all wells except for the negative control. On day 
3, 100 µl RPMI hABc with IL-2 were added to each well. On day 5, T cells were stained 
for additional surface markers and T cell proliferation was assessed by flow cytometry. 
2.2.16 Statistical analysis 
Graphpad Prism 6 was used for statistical analyses. The respective statistical tests are 
indicated in the results section. P values ≤ 0.05 were considered statistically significant.  
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3 Results 
3.1  Expression of HLA-G in healthy tissues and ovarian carcinoma  
In order to get a more detailed overview of HLA-G expression in physiological 
conditions and during ovarian carcinoma development, paraffin-embedded ovarian cancer 
samples of different subtypes and control tissues were stained for HLA-G  
3.1.1 HLA-G is expressed in few healthy tissues 
A TMA consisting of each three 1mm cores from 50 different FFPE healthy control 
tissues was immunofluorescently stained for HLA-G, cytokeratin and CD68. The 
staining, image acquisition and scoring protocols for all FFPE materials were optimized 
and carried out together with Sabine Roth and Prof. Dr. Eva Geißinger from the Institute 
of Pathology, University of Würzburg. As expected, a strong expression of HLA-G was 
detected in the placenta, particularly in the amniotic membrane. However, significant 
levels of specific HLA-G staining were also detected in the medulla of the adrenal gland 
and in seminiferous tubules of the testes. In some tissues, fluorescence detected in the 
HLA-G channel did not correlate with cellular structures and was most likely caused by 
staining artefacts. Round, spot-like artefacts were detected in spleen, liver, cortex of the 
adrenal gland and seminal vesicles. Thin, extracellular structures were positively stained 
in kidney, skin and ectocervix samples. Representative confocal images are shown in 
Figure 8, a complete overview of HLA-G expression intensities in all screened tissues is 
shown in Figure 9.  
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Figure 8: Representative examples of HLA-G expression in healthy control tissues 
A tissue microarray containing each three 1mm cores of 30 different FFPE healthy control tissue samples 
was stained for HLA-G, cytokeratin and CD68. Representative confocal images (60x magnification) from 
different control tissues are shown. HLA-G, cytokeratin and CD68 are depicted in red, blue and green, 
respectively. HLA-G was detected in the amniotic membrane, the medulla of the adrenal gland and 
seminiferous tubules. Weak fluorescence in the HLA-G channel that most likely resulted from staining 
artefacts was detected in some tissues such as skin and kidney. No specific staining was detected in most 
tissues, such as small intestine. See Figure 9 for a complete overview of HLA-G expression in all stained 
tissues.  
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Figure 9: HLA-G expression in healthy control tissues 
The tissue microarray described in Figure 8 was screened for the expression of HLA-G. HLA-G expression 
was either manually scored (A) or the average fluorescence intensity in the HLA-G channel of each image 
was quantified (B). The staining intensity was normalized to the tissue area, and mean values for all three 
spots are displayed. Specific HLA-G staining is indicated by filled bars, while fluorescence that resulted 
most likely from staining artefacts such as red blood cells is indicated by unfilled bars. 
A B 
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3.1.2 HLA-G is expressed in different subtypes of ovarian carcinoma 
In order to investigate how frequently HLA-G is expressed in different subtypes of 
ovarian carcinoma, a TMA was immunofluorescently stained as described in 3.1.1. The 
TMA contained each 4 different 0.6 mm cores from each 20 clear cell, 20 endometrioid, 
20 mucinous, 37 serous and 3 undifferentiated ovarian carcinomas. Here, all tumours 
used in the microarray had been graded according to the older FIGO 4-tier grading 
system, and no information regarding high-grade or low-grade classification was 
available. However, in studies comparing the grading systems, all grade 1 tumours were 
found to be low-grade and most grade 2 and all grade 3 ovarian carcinomas were found to 
be high-grade tumours (Malpica et al. 2004). Each spot in which HLA-G was detectable 
was both manually scored and scored based on measured fluorescence intensity in the 
HLA-G channel. Identically stained cores from ovarian epithelium and amniotic 
membrane of the control TMA were used for negative and positive controls, respectively. 
Overall, HLA-G was detected by manual scoring in cores 10 out of 37 serous, 4 out of 20 
mucinous, 3 out of 20 endometrioid, 3 out of 20 clear cell and 1 out of 3 non-
differentiated carcinomas. Compared to the healthy ovarian tissue, elevated levels of 
HLA-G expression were detected in 7 serous, 1 mucinous, 2 endometrioid and 2 clear 
cell carcinomas. Among the assessed subtypes, the lowest HLA-G expression was 
detected in non-differentiated, mucinous and clear cell carcinomas. Manually determined 
scores nicely correlated with quantified HLA-G fluorescence, which was used as a 
control. Representative examples of HLA-G immunofluorescence stainings for all 
subtypes are shown in Figure 10. HLA-G expression scores as well as grade, stage and 
age are listed for all patients in Table 2. 
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Figure 10: HLA-G is detectable by immunofluorescence in different ovarian carcinoma subtypes  
A tissue microarray containing each four 0.6 mm cores of each 20 different FFPE tumour samples of five 
ovarian carcinoma subtypes was stained for HLA-G, cytokeratin and CD68 (depicted in red, blue and 
green, respectively). As compared to healthy ovaries, elevated levels of HLA-G were detected in some 
tumours of each subtype. 
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Table 2: Results TMA HLA-G expression in ovarian carcinoma subtypes  
type grade stage age score intens.  type grade stage age score intens. 
se
ro
us
 
G1 
T1a 62 1 0.018  
m
uc
in
ou
s G1 
T3b 80 0 0.000 
T1b 67 0 0.000  T3c 51 0 0.000 
T3b 53 0 0.000  G2 T1c 40 0 0.000 T3b 53 0 0.000  T3c 62 0 0.000 
G2 
T1a 79 0 0.000  G3 T3a 65 1 0.003 T1b 32 0 0.000  T3b 59 1 0.005 
T2b 73 0 0.000  
en
do
m
et
rio
id
 
G1 
T1a 73 0 0.000 
T3a 65 0 0.000  T1a 41 0 0.000 
T3a 52 0 0.002  T1a 48 4 0.062 
T3b 79 0 0.000  T1a 38 0 0.000 
T3b 72 0 0.000  T2a 73 0 0.000 
T3b 48 0 0.000  
G2 
T1a 57 0 0.000 
T3b 83 0 0.000  T1a 52 2 0.006 
T3b 79 0 0.000  T1a 41 0 0.000 
T3b 47 0 0.000  T1a 54 1 0.016 
T3b 70 0 0.000  T1b 68 0 0.000 
T3b 65 0 0.009  T1c 64 0 0.000 
T3b 75 6 0.282  T2a 49 0 0.000 
T3c 33 0 0.000  T2c 72 0 0.000 
T3c 86 2 0.007  T3a 74 0 0.000 
G3 
T1c 71 2 0.079  T3b 51 0 0.000 
T2b 83 4 0.009  
G3 
T1b 52 0 0.000 
T2b 55 1 0.008  T1b 52 0 0.000 
T2b 44 0 0.000  T2a 50 0 0.000 
T3a 67 1 0.013  T2b 59 0 0.000 
T3b 58 0 0.000  T3c 54 0 0.000 
T3b 55 0 0.000  
cl
ea
r c
el
l 
G1 T1a 50 0 0.000 
T3b 75 0 0.000  
G2 
T1a 36 0 0.002 
T3b 58 0 0.000  T1a 60 0 0.000 
T3b 73 0 0.000  T1a 49 2 0.030 
T3b 73 0 0.006  T1a 53 0 0.000 
T3b 57 0 0.000  T1c 63 0 0.000 
T3b 52 4 0.193  T2a 63 0 0.000 
T3c 68 0 0.000  T2a 52 0 0.000 
T3c 53 0 0.000  T2b 59 0 0.000 
T3c 62 4 0.096  T3a 65 0 0.000 
T3c 60 2 0.040  T3a 56 1 0.011 
m
uc
in
ou
s 
G1 
T1a 52 0 0.000  T3c 70 0 0.000 
T1a 37 0 0.000  T3c 55 0 0.000 
T1a 62 1 0.002  T3c 49 0 0.000 
T1a 62 0 0.000  
G3 
T2a 52 0 0.000 
T1a 59 0 0.000  T3b 53 0 0.000 
T1a 39 0 0.000  T1a 68 0 0.000 
T1a 42 0 0.000  T3a 67 0 0.000 
T1a 61 0 0.000  T3a 83 2 0.028 
T1a 54 0 0.000  T3b 75 0 0.000 
T1a 63 0 0.000  
N
D
 
G4 
T2b 73 0 0.002 
T1a 73 0 0.000  T3b 49 1 0.003 
T1c 78 0 0.000  T3b 76 0 0.000 
T2b 40 2 0.017  healthy ovary 49 1 0.033 
T2b 40 0 0.000  healthy placenta 21 9 0.601 
Each four 0.6 µm cores stained for HLA-G, cytokeratin and CD68 were analysed from each patient; score = 
highest manually determined HLA-G expression score of one tumour, intens. = mean detected HLA-G 
fluorescence intensity of all spots [% of maximum detectable intensity]; ND = non-differentiated; healthy 
ovary = ovarian epithelium from healthy donor; healthy placenta = amniotic membrane from normal term 
placenta; three 1 µm cores of these control tissues were stained in parallel on a different microarray and 
included in this table for reference.  
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3.1.4 Most HLA-G is detectable in high-grade serous carcinomas  
In serous carcinomas, moderate to high HLA-G expression levels (score > 1) were 
detected in none of 4 grade 1 (low-grade) tumours, 2 out of 16 grade 2 tumours (which 
are mostly high-grade; HLA-G expressing tumours were stage T3b and T3c) and in 5 out 
of 17 grade 3 (high-grade) tumours. This trend, which has also been reported by others 
(Menier, Prevot et al. 2009, Singer, Rebmann et al. 2003), was observed with regards to 
only serous (see Figure 11) or all carcinoma subtypes (see Figure 12). However, due to 
the low sample numbers, this difference did not reach statistical significance (P=0.16 and 
P=0.08, respectively; unpaired Student’s t-Test; one-tailed). HLA-G expressing tumours 
were detected in all stages and patients of all ages (see Figure 12).  
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Figure 11: HLA-G may most frequently be expressed by high-grade, serous carcinomas 
HLA-G expression was quantified with similar results by (A) quantifying the staining intensity or by (B-D) 
manual scoring (highest detected score for each patient is indicated). (B) Most of the tumours that 
expressed high levels of HLA-G (above dashed line) were serous carcinomas (C) of grade 2 or 3 and (D) 
stage T2 or T3. Only serous carcinomas are shown in (C and D).  
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Figure 12: HLA-G is most frequently expressed by grade 3 carcinomas irrespective of stage or patient age  
When all ovarian carcinoma samples included in the TMA are analysed together, the trend that grade 3 
express most HLA-G is confirmed (A). However, no correlation with tumour stage (B) or age of the 
patients at time of surgery (C) was found. Samples were from patients between 32 and 86 years of age. 
HLA-G-expression was detected in carcinomas from patients of age 40 to 86.  
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3.1.5 In primary lesions, HLA-G is predominantly expressed by malignant cell  
In order to confirm HLA-G expression on malignant cells, some consecutive slides were 
additionally stained for tumour markers Wilms tumour protein (WT1) and cytokeratin. 
As shown in Figure 13, HLA-G was mostly detected on cytokeratin-positive, WT1-
postitive or double-positive tumour cells.  
 
Figure 13: HLA-G is predominantly expressed by ovarian carcinoma cells in primary lesions  
Three FFPE sections of the same tumour area were stained by IHC for the tumour markers wilms tumour 
protein (WT1) and cytokeratin and for HLA-G. In primary tumours, HLA-G was mostly detected in cells 
that expressed these tumour markers and were of malignant morphology. 
3.1.6 HLA-G is detectable in metastases and histiocytes in local lymph nodes  
Ovarian carcinomas frequently metastasize into draining lymph nodes within the pelvis or 
to pelvic organs, such as the omentum majus (Jayson, Kohn et al. 2014). In order to 
investigate whether HLA-G is also expressed in metastases, FFPE primary metastases 
and lymph node samples were stained for HLA-G. As high-grade serous ovarian 
carcinomas most frequently expressed HLA-G and due to the availability of FFPE lymph 
node samples from, only samples of this subtype were analysed here. In contrast to the 
TMA in which 4 0.6 µm cores from 100 different tumours were analysed on one slide, 
here only 1 or 2 tumour or lymph node sections were analysed per slide. The sections 
were mostly between 5 and 15 mm in diameter. Thus, in these samples, a much higher 
fraction of the tumour was screened for HLA-G expression. Lymph nodes that were 
assessed here belonged to the nodi lymphatici (Nll) paraaortica, iliaci communes, interni 
and externi and obturatori (see Figure 14). 
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Figure 14: Anatomical sites of patient lymph nodes screened for HLA-G expression 
Lymph nodes from high-grade serous carcinoma patients that were screened for HLA-G were from the 
following sites: nodi lymphatici (Nll) paraaortica, iliaci communes, interni and externi and obturatori. A 
short part of the aorta is shown in red. Lymph nodes (green) and the ovary (orange) of one side only are 
depicted. 
 
In tumour sections from primary lesions, significant HLA-G-staining was detected in 
samples of 9 out of 11 patients with high-grade serous carcinomas (11 out of 13 different 
sections). HLA-G was also expressed in metastases of 6 out of 7 patients (8 out of 10 
sections), although at significantly lower expression levels (P=0.033, unpaired Student’s 
t-Test; two-tailed). HLA-G expression within different areas of one tumour was usually 
heterogeneous (see Figure 15). Surprisingly, high levels of HLA-G were also detected on 
histiocytes in lymph nodes with and without metastases, even in cases in which no 
HLA-G was detectable in the primary lesion (see Table 3). In contrast, no HLA-G was 
detectable in tonsils from non-malignant donors which were used as a reference tissue for 
secondary lymphoid organs. Furthermore, only marginal levels of HLA-G were detected 
in immunofluorescently stained lymph nodes from healthy donors (see Figure 9). Thus, 
HLA-G may be induced in or transferred to histiocytes in tumour-free lymph nodes. 
Representative IHC stainings of tonsils from non-malignant patients, primary lesions and 
lymph nodes with and without metastases and histiocytes from serous carcinoma patients 
are shown in two different magnifications in Figure 15.  
HLA-G staining of malignant cells in primary tumours and metastases and histiocytes in 
lymph nodes was manually scored in order to be able to compare expression levels in 
between these tissues. Reference sections that were used for scoring the HLA-G staining 
intensity on tumour cells and histiocytes are shown in Figure 16. HLA-G expression 
scores in these tissues are listed for all patients in Table 3 and compiled in Figure 17 
where patient-specific symbols are used.  
ovaryNll. paraaortica
Nll. iliaci communes
Nll. iliaci interni
Nll. iliaci externi
Nll. obturatori
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Figure 15: Representative examples of tumours and lymph node sections stained by IHC for HLA-G 
FFPE primary tumour, metastases and lymph node samples from high-grade serous carcinoma patients 
were stained by IHC with the anti-HLA-G antibody 4H84. HLA-G was expressed at high levels in most 
primary tumours and at lower levels in most metastases. HLA-G was also detected on histiocytes (indicated 
by arrows) in local tumour-free lymph nodes and lymph nodes with metastases. No HLA-G was detected in 
tonsils from non-tumour patients or in healthy lymph nodes (see Figure 9).  
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Figure 16: Reference sections for IHC HLA-G intensity scoring 
The HLA-G staining intensity in primary tumour and lymph node (LN) sections was manually scored by 
evaluating the intensity on a scale from 0 to 3. Reference images are shown. For the expression score, this 
intensity value was multiplied by 0, 1, 2, 3 or 4 when stained cells were found in 0%, 1-10%, 10-25%, 25-
50%, or 50-100% of the tumour or lymph node area, respectively. As an example, the highest possible 
expression score of 12 is given if a very intense HLA-G staining is detected in more than 50% of carcinoma 
cells or histiocytes. 
 
 
Table 3: HLA-G expression scores in malignant cells and on histiocytes 
patient # tumour cells primary lesion 
tumour cells  
metastasis 
histiocytes in LN  
without metastases 
histiocytes in LN  
with metastases 
1 8   6/9/3/4/3 
2 9/6 4/1 6/6 4/6/9 
3 6/2 3/0 6 6/3 
4 8/6 4/3 12/12 12 
5 2 3  6 
6 0 2/0 6/3  
7 8/6  6 9 
8 6 6 9 1 
9 0   2/0 
LN = lymph node, expression scores for each available sample are indicated and separated by / symbols. In 
some cases, several parts of the primary tumour were assessed. 
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Figure 17: HLA-G is detected in primary tumours, metastases and histiocytes in local lymph nodes. 
HLA-G IHC staining intensity was scored in FFPE primary tumour, metastases and lymph node samples 
from 9 high-grade serous carcinoma patients. In some patients, several tumours or lymph nodes were 
assessed. Each patient is represented by an individual symbol. Most assessed tumour samples expressed 
HLA-G both in primary tumours and, in significantly lower amounts, in metastases (P=0.033, unpaired 
Student’s t-Test; two-tailed). HLA-G was detected on histiocytes in at least one lymph node section in all 
of the assessed patients. 
tumour cells
primary lesion
tumour cells
metastasis
histiocytes
LN without met
histiocytes
LN with met
0
4
8
12
H
LA
-G
 s
ta
in
in
g 
sc
or
e 
FF
PE
*
3 Results 
 
 
    71 
3.2 HLA-G and MHC Ia expression correlate in ovarian carcinomas 
In order to investigate whether HLA-G expression may enable otherwise immunogenic 
ovarian carcinomas to escape from immunosurveillance, a published gene expression 
dataset was screened for mRNAs which correlate with HLA-G mRNA expression. A 
dataset from a microarray-based study that included gene expression data from 285 
carcinomas of the ovary, peritoneum, and fallopian tube was selected (Tothill et al. 
2008). The R2 genomics analysis and visualization platform (http://r2.amc.nl) was used 
to find genes expressed at high levels HLA-G expressing tumours. Interestingly, among 
the seven mRNAs expressed in highest correlation with HLA-G mRNA (all P <10-77) 
were, in addition to HLA-E and HLA-F, mRNAs from all classical MHC class Ia genes 
(HLA-A, -B and -C) and TAP1, which is involved in transporting and loading antigenic 
peptides to MHC class I molecules (Momburg and Tan 2002, Raghuraman et al. 2002) 
(see also Table 4). Two X-Y plots of these almost linear correlations (indicated by R2 
values ranging form 0.85 to 0.95) are displayed in Figure 18. 
Table 4: HLA-G expression correlates with MHC Ia and TAP1 expression in ovarian carcinomas 
gene R2 P value Function Reference 
HLA-G 1.000 0.0e+00 see introduction  
HLA-J 0.946 8.6e-137 inactivated gene (Messer et al. 1992) 
HLA-F 0.945 3.9e-136 MHC Ib see introduction 
HLA-B 0.897 2.1e-98 antigen presentation (Neefjes, Jongsma et al. 2011, Williams et al. 2002) 
HLA-E 0.889 3.0e-94 MHC Ib see introduction 
HLA-C 0.887 2.0e-93 antigen presentation (Neefjes, Jongsma et al. 2011, Williams, Peh et al. 2002) 
HLA-A 0.883 1.1e-91 antigen presentation (Neefjes, Jongsma et al. 2011, Williams, Peh et al. 2002) 
TAP1 0.852 2.7e-78 peptide transport/ MHC loading 
(Momburg and Tan 2002, 
Raghuraman, Lapinski et al. 
2002) 
Source: (Tothill, Tinker et al. 2008) dataset analysed with R2 (http://r2.amc.nl) 
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Figure 18: HLA-G and HLA-B and TAP1 gene expression correlate in ovarian cancer 
The R2 genomics analysis and visualization platform (http://r2.amc.nl) was used to analyse genes 
expressed in correlation with HLA-G in ovarian cancer (Tothill, Tinker et al. 2008). HLA-B and TAP1 are 
both involved in antigen presentation and their expression highly correlated with HLA-G expression. 
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3.3 Induction of HLA-G in immune cells  
3.3.1 Ascites of ovarian carcinoma patients often contains high levels of IL-4 and 
IL-10 
It has been reported that dendritic cells that are generated in the presence of IL-10 in 
addition to IL-4 and GM-CSF (DC-10) express high levels of HLA-G (Gregori, 
Tomasoni et al. 2010). Furthermore, IL-10 has been reported to induce HLA-G in 
trophoblasts and monocytes of some donors (Moreau et al. 1999) and IL-4 may induce 
the expression of soluble HLA-G5 in T cells (Lombardelli, Aguerre-Girr et al. 2013).  In 
order to investigate whether IL-4 and IL-10 may also induce the observed HLA-G 
expression in dendritic cells in lymph nodes in ovarian cancer, concentrations of both 
cytokines were measured by ELISA in ascites derived from ovarian carcinoma patients. 
High concentrations of both cytokines were frequently detected in ascites from OvCa 
patients, but also in benign ascites (physiological serum levels are indicated by dotted 
lines in Figure 19).  
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Figure 19: Ovarian carcinoma ascites contains high levels of IL-4 and IL-10  
IL-4 (A) and IL-10 (B) in ascites samples from 24 ovarian carcinoma (OvCA) patients and 7 patients 
without malignancy were quantified by ELISA. As ascites does not accumulate in healthy individuals, 
physiological serum levels of each cytokine as reported in the literature (Sheu and Shih Ie 2007) are 
indicated by the dotted lines for reference. Highly elevated concentrations of both cytokines were detected 
in some benign and most ovarian carcinoma ascites samples.  
3.3.2 IL-4 and IL-10 induce HLA-G expression in lymphocytes, but not in 
monocytic cells 
In order to investigate whether HLA-G expression in histiocytes may be induced due to 
high levels of IL-4 or IL-10, we tested if these cytokines induce HLA-G in monocytes or 
monocyte-derived dendritic cells from healthy donors. Monocytes were isolated either by 
adherence enrichment or via anti-CD14 magnetic beads. Within 48 hours, both IL-4 and 
IL-10 induced the expression of HLA-G on protein level both in adherence-enriched 
monocytes and CD14- lymphocytes. However, no induction or basal expression was 
detected in bead-purified CD14+ cells. Flow cytometry revealed that only between 25% 
and 63% of adherence-enriched cells were actually CD14+ monocytes (see Figure 20). 
Thus, HLA-G detected in adherence-enriched monocytes may be derived from 
contaminating lymphocytes. Similarly, DC-10 cells derived from bead-purified 
monocytes did not express HLA-G (see Figure 24A LCL ctrl SN lane). 
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Figure 20: IL-4 and IL-10 induce HLA-G in lymphocytes, but not in monocytes  
(A) Adherence-enriched and both CD14+ and CD14- fractions from bead-purified PBMCs were left 
untreated or treated with IL-4, IL-10, or both cytokines for 48 hours. HLA-G-expression was quantified by 
Western Blotting. The experiment was repeated three times, a representative example is shown. (B) In 
different experiments, only 25-65% of adherence-enriched viable cells were CD14+ monocytes, while 
anti-CD14 bead-based purification repeatedly resulted in purities of more than 90%. (C) Gating strategy for 
one representative example. 
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3.3.3 IL-4 may induce HLA-G expression in T cells 
It has previously been reported that IL-4 (Lombardelli, Aguerre-Girr et al. 2013) and 
IL-10 induce HLA-G expression (Gregori, Tomasoni et al. 2010, Moreau, Adrian-
Cabestre et al. 1999, Urosevic and Dummer 2003). Here, we found that both cytokines 
induce HLA-G expression on protein level in PBL, but not in monocytic cells. Thus, we 
set out to investigate whether these cytokines may also upregulate HLA-G expression on 
mRNA level. HLA-G mRNA was quantified untreated and IL-4 or IL-10 treated immune 
cell subpopulations. As HLA-G expression had been detected on dendritic cells in lymph 
nodes, we focussed on membrane-bound HLA-G (mHLA-G) mRNA. To this end, a 
highly sensitive and quantitative TaqMan PCR assay was developed (see 2.2.11).  
CD14+ monocytes, CD4+ and CD8+ T cells and NK cells were then isolated by magnetic 
beads. These cells were left untreated or treated with 10 ng/ml IL-4 or IL-10 for 6 hours. 
RNA was isolated, reversely transcribed and mHLA-G cDNA was quantified. In 
acordance with Western Blotting results, only very low HLA-G mRNA levels were 
detected in purified CD14+ and NK cells. In contrast, higher mRNA levels were 
detectable in T cells, which were significantly increased in CD4+ cells in response to IL-4 
treatment. Jeg-3 choriocarcinoma cells which were used as positive control expressed 
more than 100 fold more HLA-G mRNA than untreated T cells (see Figure 21A).  
Subsequently, it was investigated whether IL-4 may also induce the expression of HLA-G 
protein on the cell surface of different lymphoid cells. Here, PBMCs were left untreated 
or treated with 10 ng/ml IL-4 for 48 hours. HLA-G surface expression was detected by 
flow cytometry in a small fraction of T and NK cells, and this fraction was increased in 
response to IL-4 treatment in three independent experiments (see Figure 21B), however, 
to a highly donor-dependent extent. Here, monocytes were not analysed due to high 
autofluorescence and unspecific binding of both specific and isotype antibodies, which 
could not be sufficiently blocked.  
3 Results 
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Figure 21: IL-4 may induce HLA-G expression in T cells 
(A) Bead-purified CD14+, CD4+, CD8+ and NK cells were left untreated or treated with IL-4 for 6 hours. 
HLA-G induction on mRNA level was quantified by TaqMan qPCR. Means and standard deviations of 
technical replicates are shown, mRNA expression was statistically analysed in each cell type by individual 
T tests. (B) PBMCs from healthy donors were treated with IL-4 of left untreated for 48 hours. HLA-G 
surface expression in different subsets of immune cells was quantified by flow cytometry.  All experiments 
were repeated three times with similar, yet donor-dependent results. Representative examples are shown. 
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3.4 Transfer of soluble HLA-G to monocytic cells 
As HLA-G was not inducible in monocytes or monocyte-derived dendritic cells from 
healthy donors and basal expression levels were very low, we investigated whether these 
cells are capable of binding soluble HLA-G that may be produced by tumour cells. 
Several mechanisms of transfer have been described for HLA-G, such as trogocytosis and 
transfer via exosomes. Furthermore, monocytes were reported to bind soluble HLA-G 
tetramers predominantly via the ILT4 receptor (Biancotto et al. 2013, Kleiner et al. 
2013). Thus, we hypothesized that tumour-derived sHLA-G may be specifically 
transferred to myeloid cells via the ILT4 receptor. In order to test this hypothesis, it was 
investigated whether soluble HLA-G is present in high concentrations in the tumour 
microenvironment. Furthermore, the surface expression levels of ILT4 receptors on PBL 
and DC were quantified. Finally, it was investigated whether DC bind soluble HLA-G 
derived from supernatants of HLA-G5 transfected tumour cells.  
Some experiments in this section were done together with Tamara Kuhfuß and, when 
indicated, published in part in her Bachelor of Science thesis entitled “Transfer von 
löslichem HLA-G auf dendritische Zellen – ein neuer immune escape Mechanismus im 
Ovarialkarzinom?” (transfer of soluble HLA-G to dendritic cells – a novel immune 
escape mechanism in ovarian cancer?). 
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3.4.1 Ascites samples from ovarian carcinoma patients contain soluble HLA-G  
High levels of soluble HLA-G (sHLA-G) have previously been reported to be present in 
ascites (Allan et al. 1999) and serum (Singer, Rebmann et al. 2003) of ovarian carcinoma 
patients. In order to confirm that sHLA-G is present in the tumour microenvironment, 
ascites samples from ovarian carcinoma patients were screened for sHLA-G by ELISA. 
In accordance with the literature, ovarian carcinoma ascites contained significantly more 
sHLA-G as compared to benign ascites samples (P=0.022, unpaired T Test, one-tailed). 
In detail, 10 out of 20 ovarian carcinoma ascites samples but none of the benign ascites 
samples contained more sHLA-G than the arbitrary threshold of 5 ng/ml (see Figure 22).  
 
Figure 22: Ascites from ovarian carcinoma patients contains elevated levels of sHLA-G. 
sHLA-G was quantified by ELISA in 20 ovarian carcinoma ascites samples and 5 benign ascites samples. 
sHLA-G levels were found to be elevated in ovarian carcinoma ascites samples as compared to benign 
ascites (P=0.022, unpaired Student’s t-Test, one-tailed). Concentrations above the arbitrary threshold of 5 
ng/ml (dashed line) were detected in 10 out of 20 ovarian carcinoma ascites samples but in none of the 5 
benign ascites samples. The detection limit was 1 ng/ml.  
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3.4.2 DC and particularly DC-10 express ILT4 
It has been reported that HLA-G tetramers bind to monocytes in an ILT4-dependent 
manner (Mach et al. 2010). In contrast to ILT2 which is expressed in both lymphoid and 
monocytic cells, ILT4 is reported to be exclusively expressed by monocytes, 
macrophages and dendritic cells (Allan, Colonna et al. 1999). DC-10 cells that are 
cultured in the presence of not only IL-4 and GM-CSF but also IL-10 for 7 days have 
been reported to express particularly high levels of ILT4 (Colonna, Samaridis et al. 
1998). Thus, this receptor could play a role decisive role in the selective transfer of 
soluble HLA-G to monocytic cells. 
In order to confirm these findings, surface expression of ILT4 on CD4+ and CD8+ T cells, 
NK cells, DC and DC-10 was quantified by flow cytometry. ILT4 was detected on DC 
cultured with GM-CSF and IL-4 and on CD11c+, CD68+, HLA-DR+ DC-10 (Gregori, 
Tomasoni et al. 2010). As expected, DC-10 expressed significantly higher levels of ILT4 
(see Figure 23). These experiments were done together with Tamara Kuhfuss and have 
been presented in part in her B.Sc. Thesis. 
 
  
3 Results 
 
 
    81 
    
 
                                 
                       
 
 
Figure 23: DC-10 express more ILT4 on the cell surface than DC 
Anti-CD14 bead-purified monocytes from 2 healthy donors were matured for 7 days in the presence of IL-4 
and GM-CSF (DC, elsewere also referred to as immature DC) or IL-4, IL-10 and GM-CSF (DC-10). 
Freshly isolated PBL were included as controls. DC and DC-10 were stained with fluorescently labelled 
antibodies for CD11c, CD86, HLA-DR, and ILT4. (A) DC-10 (red curve, black=isotype antibody) express 
significantly more ILT4 as compared to DC (blue curve, grey=isotype antibody, P=0.0011, unpaired T 
Test, two-tailed, mean and SD from 3 independent experiments are shown), which express significantly 
more ILT4 than ILT4- leukocytes. (B) DC-10 are CD11c+, CD86+ and HLA-DR+.  
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3.4.3 DC-10 efficiently bind soluble HLA-G5  
Because of the high expression of ILT4 on DC-10 it was subsequently investigated 
whether these cells may bind soluble HLA-G. Here, supernatant of LCL cells transfected 
with a single chain construct consisting of HLA-G5, a linker and β2-microglobulin 
(single chain HLA-G5, here abbreviated scHLA-G5) was used as a source of HLA-G 
(kind gift of Dr. Joel LeMaoult). Natural isoforms of HLA-G such as HLA-G1 and 
HLA-G5 dissociate from β2-microglobulin under denaturing conditions and are then 
detectable by Western Blotting as a 39 kDa band. In contrast, scHLA-G5 can be detected 
as a 50kDa band and is thus clearly distinguishable from any natural isoform. In three 
independent experiments, no endogenous HLA-G was detected in DC-10 cells derived 
from bead-purified monocytes or DC-10 treated with mock-transfected control 
supernatants (see Figure 24A LCL ctrl SN lane). However, DC-10 cells efficiently bound 
high amounts of scHLA-G5 from the supernatant, which was detectable by Western 
Blotting after stringent washing of the cells (see Figure 24A LCL scHLA-G5 SN lanes). 2 
hours were sufficient for transferring high amounts of scHLA-G. Transfer occurred both 
at 37°C and, during shorter incubation periods to a slightly lesser extent, at 4°C. These 
experiments were done together with Tamara Kuhfuss and have been presented in part in 
her B.Sc. Thesis. 
      
Figure 24: DC-10 cells efficiently bind soluble HLA-G from supernatants at 4°C and 37°C. 
2.5 x 105 DC-10 cells each were incubated for 2, 4, 6 or 24h at 4°C or 37°C with 100 µl DC medium plus 
100 µl LCL scHLA-G5 SN or LCL ctrl SN. Cells were then washed three times with 10 ml prewarmed 
PBS and cell pellets were lysed in lysis buffer. (A) HLA-G and β-actin were detected by Western Blotting 
and (B) quantified by measuring band sizes and intensities with ImageJ.  
2h   
 4°
C
37
°C
4°
C
37
°C
4°
C
37
°C
4°
C
37
°C
37
°C
HLA-G
β-actin
- 50 kDa
- 40 kDa
    4h       6h       24h   
LCL scHLA-G5 SN
LCL
ctrl
SN
2 4 6
0.0
0.5
1.0
24
hours
H
LA
-G
 n
or
m
al
iz
ed
 to
β
-a
ct
in 4°C
37°C
ctrl SN
A 
 
B 
3 Results 
 
 
    83 
3.4.4 Blocking of ILT receptors reduces binding of HLA-G5  
In order to verify that ILT receptors are involved in the transfer of sHLA-G to DC-10 
blocking experiments were subsequently carried out. In three independent experiments, 
the addition of antibodies that block HLA-G, ILT2 or ILT4 to scHLA-G5 SN reduced the 
amounts of soluble scHLA-G5 bound by DC-10 cells. A representative example is shown 
in Figure 25. These experiments were carried out together with Lina Hilscher. 
 
 
Figure 25: Antibodies directed against HLA-G, ILT2 or ILT4 block the transfer of sHLA-G to DC-10. 
2.5 x 105 DC-10 cells were incubated for three hours with LCL scHLA-G5 SN plus isotype or blocking 
antibodies (10µg/ml) at 37°C. Cells were stringently washed, lysed and bound scHLA-G5 and intracellular 
β-actin were detected by Western Blotting. LCL scHLA-G5 SN containing 5 ng scHLA-G5 was directly 
loaded on the first lane as a positive control.  
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3.5 DC-10 loaded with HLA-G5 are more immunosuppressive 
As discussed in the introduction, HLA-G is known to exert suppressive effects on various 
immune cells. Furthermore, we have detected high levels of HLA-G on dendritic cells in 
tumour-draining lymph nodes, which may be transferred tumour-derived soluble HLA-G. 
In order to test whether dendritic cells that have absorbed HLA-G may be more 
immunosuppressive, it was investigated whether DC-10 cells loaded with scHLA-G5 
(DC-10scHLA-G5) may induce regulatory T cells or inhibit CD8+ effector T cell 
proliferation.  
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3.5.1 DC-10 loaded with HLA-G5 induce regulatory T cells 
It has previously been shown that both HLA-G and DC-10 may contribute to the 
induction of Tregs (Gregori, Tomasoni et al. 2010). Thus, it was tested whether transferred 
HLA-G may amplify DC-10-mediated Treg induction. PBL in Treg medium were either 
left untreated or DC-10ctrl or DC-10scHLA-G5 from the same healthy donor were added. 
After 6 days, the percentage of FoxP3+ Treg cells among CD4+ cells was quantified by 
intracellular staining and flow cytometry. In three independent experiments, a clear 
induction or expansion of Treg was detected after coculture with DC-10ctrl, and, to a higher 
extent, after coculture DC-10scHLA-G5 cells. A representative experiment is shown in 
Figure 26. Some of these experiments were done together with Tamara Kuhfuss and have 
been presented in part in her B.Sc. Thesis. 
    
 
              PBL                              PBL+DC-10ctrl                PBL+DC-10sHLA-G 
       
 
                FoxP3 
 
Figure 26: DC-10 and particularly DC-10scHLA-G5 induce CD4+ FoxP3+ regulatory T cells 
DC-10 cells were generated as described before, incubated for 3 hours at 37°C with LCL ctrl supernatant 
(DC-10ctrl) or LCL-scHLA-G5 supernatant (DC-10scHLA-G5) and washed three times with prewarmed PBS. 
106 PBL in Treg medium were either left untreated or 5 x 104 DC-10ctrl or DC-10scHLA-G5 from the same 
healthy donor were added. At day 6, cells were stained for extracellular markers CD4 and CD8 and for 
intracellular FoxP3 and analysed by flow cytometry. The percentage of Treg cells (CD4+Fox+ gate) induced 
was highly donor-depent, but DC-10scHLA-G5 induced most Treg in three independent experiments. A 
representative experiment is shown. 
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3.5.2 Fixed DC-10scHLA-G5 inhibit CD8+ T cell proliferation 
sHLA-G bound by DC-10 cells enhances their capacity induce Treg. However, it remained 
unclear whether these effects on T cells were mediated directly via HLA-G bound to the 
cell surface of DC-10 or indirectly through ILT-receptor mediated upregulation of 
immunosuppressive molecules on DC-10 cells. Thus, it was tested whether DC-10scHLA-G5 
that are fixed with paraformaldehyde and thus incapable of upregulating or secreting any 
immunosuppressive molecules are also more immunosuppressive as compared to 
identically treated DC-10ctrl. Here, we tested whether effects on the proliferative capacity 
of syngeneic CD8+ T cells are detectable. In three independent experiments, fixed DC-
10scHLA-G5 inhibited the PHA-induced proliferation of cell-proliferation dye eFluor 670-
stained CD8+ T cells to a higher extent as compared to fixed DC-10ctrl. A representative 
example is shown in Figure 27. 
       
  
 
Figure 27: DC-10scHLA-G5 strongly inhibit CD8+ T cell proliferation 
DC-10 cells were generated as described before, incubated for 3 hours at 37°C with LCL ctrl supernatant 
(DC-10ctrl) or LCL-scHLA-G5 supernatant (DC-10scHLA-G5) and washed three times with prewarmed PBS. 
DC-10 were then fixed for 10 minutes with 1% PFA and washed 3 more times. 4 x 105 syngenic PBL from 
the same healthy donor were stained with eFluor 670 Cell Proliferation Dye and either left untreated (grey 
line), treated with PHA (2.4ng/ml, black line) or with PHA and 1 x 105 fixed DC-10ctrl (blue line) or PHA 
DC-10scHLA-G5 (red line). PHA-induced CD8+ T cell proliferation indicated by peaks with diluted eFluor 
concentrations was inhibited particularly in presence of DC-10scHLA-G5 cells. A representative example of 
three independent experiments is shown.  
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4 Discussion 
Due to its potent immunosuppressive effects, HLA-G possesses the ability to protect 
altered or foreign tissues from immunological destruction. This effect has been 
demonstrated in a xenograft study, in which HLA-G transfected human melanoma cells 
grew for about 3 days in completely immunocompetent mice. Moreover, complete 
tumour rejection required more than two weeks, while non-transfected melanoma cells 
were immediately rejected (Agaugue et al. 2011). Here, HLA-G most likely interacts 
with paired immunoglobulin-like inhibitory receptor (PIR-B), the mouse homologue of 
ILT4 (Liang et al. 2002). While some researches have stated that there is no direct 
homologue for HLA-G in the mouse (Agaugue, Carosella et al. 2011), the murine 
MHC Ib molecule Qa-2 shares many features with HLA-G. It presents nonapeptides, 
exists in membrane-bound and soluble isoforms, possesses a short cytoplasmic tail and is 
expressed in preimplantation embryos where it enhances survival and promotes 
embryonic growth (reviewed by Comiskey et al. 2003). Alternatively, blastocyst MHC 
could be a functional homologue. It is expressed in the placenta and able to protect 
tumour cells from immunological assault (Tajima et al. 2003). Of note, the amino acid 
sequences of the alpha 3 domains of both molecules are more than 92% identical 
(alignment see Supplements Table 7).   
HLA-G is essential during embryogenesis (Rizzo, Vercammen et al. 2011, Verloes, Van 
de Velde et al. 2011), may play an important role in autoimmune diseases (Rizzo et al. 
2014), could protect pathogens such as viruses (Amiot et al. 2014, Rizzo, Bortolotti et al. 
2014) and is apparently perilous in a high proportion of malignant diseases. In this 
context, novel insights into the function of HLA-G in physiological and malignant 
processes that were obtained in this thesis will be discussed.  
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4.1 Physiological role and expression of HLA-G  
Due to the limited availability of tissues from healthy donors, it was decided to use a 
FFPE tissue microarray to study HLA-G expression. This approach has several 
advantages. As opposed to staining individual sections, the required time and resources 
are lowered, and technical variability due to slight alterations during the staining process 
are less likely. Furthermore, it takes less time to switch in between samples during 
evaluation, which may lead to a more accurate scoring. However, due to the small size of 
the cores, small anatomical structures or heterogeneously expressed proteins may not be 
detectable in all samples. This can be partially compensated for by combining several 
cores from each tissue in one microarray.  
In contrast to ubiquitously expressed MHC class Ia molecules which enable the immune 
system to detect malignant or infected cells throughout the body, only very few tissues 
have been reported to physiologically express HLA-G.  
In accordance with the literature, we detected the highest physiological HLA-G 
expression level in the placenta (see Figure 8). This confirms the suitability of the used 
staining protocol and suggests that HLA-G molecules have been well preserved in 
microarray tissues obtained from surgery. As discussed in the introduction, HLA-G 
expression on cytotrophoplast cells is most likely required to prevent the maternal 
immune system from attacking and rejecting of embryonic tissues. Tolerance towards 
“self” tissues usually depends on the depletion of autoreactive T cells within the thymus, 
where also tolerogenic Treg cells are generated. However, embryos express paternal MHC 
molecules, may have different serotypes and express thousands of paternal proteins 
which may either contain slightly altered protein sequences or are completely different, 
such as proteins encoded for by the Y chromosome. As none of these factors are present 
within the maternal thymus, there should also be no pre-existing tolerance towards 
embryonic tissues. As observable in skin allograft transplantation experiments in mice 
(Steinmuller et al. 1982), these factors should lead to immediate rejections of non-
matched transplanted organs, unless immunosuppressive therapeutics are given (Ruiz et 
al. 2013) or the transplanted organ is from a immunoprivileged site (Streilein 2003). 
Thus, each successful pregnancy is an enourmous immunological challenge, which has 
fascinated immunologists for more than 60 years (Medawar 1953). In fact, the risk for 
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spontaneous pregnancy loss particularly in the first trimester is higher than 10% even in 
young and healthy parents and increases with parental age (de la Rochebrochard and 
Thonneau 2002, Garcia-Enguidanos et al. 2002).  
One of the most important factors to protect embryos from rejection is thought to be 
HLA-G (Hunt, Langat et al. 2006). As previously mentioned, embryonic HLA-G 
expression correlates with successful pregnancies (Rizzo, Vercammen et al. 2011). 
Reduced soluble HLA-G serum levels during early or late pregnancy (Hackmon et al. 
2007, Yie et al. 2004, Yie et al. 2005) and altered HLA-G transcription (O'Brien et al. 
2001) correlate with preeclampsia, which usually occurs during the last trimester 
(Steegers et al. 2010). Preeclampsia may be triggered by maternal Th1 immune reactions 
towards embryonic tissues (Visser et al. 2007), occurs in 5%-10% of all pregnancies (Le 
Bouteiller et al. 2003) and is the leading cause of infant and maternal death during 
pregnancies.  
In addition to the immunological challenge, significant anatomical changes must be 
induced during a successful pregnancy. First, the blastocyst must implant in the 
endometrium of the uterus, and the trophoectoderm cells must further invade this tissue to 
form a placenta that ensures sufficient transport of nutrients towards the fetus. 
Interestingly, HLA-G may also promote vascularisation through interactions with 
decidual NK cells (Rajagopalan et al. 2006, Rajagopalan and Long 2012). Furthermore, 
the knockdown of HLA-G mRNA in zygotes significantly slowed down embryonic 
development (Yao, Shu et al. 2014).  
From this perspective, it makes sense that HLA-G is also expressed within testicular 
tissues such as seminiferous tubules (see Figure 9). HLA-G has previously been detected 
in seminal fluids (Verloes, Van de Velde et al. 2011, Yao, Shu et al. 2014), and may thus 
help to prevent maternal immune reactions towards antigens on sperm cells. Thus, the 
most important physiological function of HLA-G may be the protection of embryonal 
tissues. 
However, HLA-G has also been detected in adult tissues. One of them is the cornea (Le 
Discorde, Moreau et al. 2003), which is widely recognised as an immune privileged 
tissue. Corneas have first been successfully transplanted more than hundred years ago, 
and are often not rejected even when donors and recipients are not matched (Moffatt et 
al. 2005). Unfortunately, cornea tissue was not included in the microarray. 
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Furthermore, HLA-G has been detected in the thymus (Mallet, Blaschitz et al. 1999) and 
in the pancreas (Cirulli, Zalatan et al. 2006). HLA-G was not detectable in either of these 
tissues in the FFPE cores included in the microarray. However, in the thymus, HLA-G 
has been described to be present in medullary thymic epithelial cells only. These cells 
express the autoimmune regulator AIRE and produce protein fragments from most 
proteins in the human genome which are required for negative T cell selection and Treg 
induction (Coquet et al. 2013, Leavy 2013). Soluble HLA-G could play an important role 
in these processes, as soluble HLA-G induces regulatory T cells (Le Rond et al. 2006) 
and may induce apoptosis in CD8+ effector cells (Contini, Ghio et al. 2003). On the other 
hand, HLA-G expression could be randomly induced under control of the AIRE complex.  
In the pancreas, HLA-G has been detected only on islet cells (Cirulli, Zalatan et al. 2006). 
These islets produce insulin and other hormones. In our study, HLA-G may have not 
been detectable in both the pancreas and the thymus because the comparatively rare 
relevant cell subsets were not present in the small microarray cores. 
However, we have found a significant HLA-G expression within the adrenal medulla. In 
analogy to the islet cells in the pancreas, this endocrine tissue mostly produces hormones 
such as adrenalin and noradrenalin, but it is not immediately obvious why 
immunosuppressive molecules such as HLA-G are expressed here. To our knowledge, 
HLA-G expression in the adrenal medulla has not been previously described. However, 
moderate levels of mRNA of Mamu-AG, the rhesus monkey homologue of HLA-G 
(Gregori et al. 2009, Moreau, Adrian-Cabestre et al. 1999, Naji et al. 2007) have been 
detected in rhesus monkey adrenal glands (Slukvin et al. 1999). 
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4.2 HLA-G expression in ovarian carcinomas 
High expression levels of HLA-G have been detected in a wide variety of cancers 
(Amiot, Ferrone et al. 2011), including ovarian carcinomas (Lin, Yan et al. 2007, Menier, 
Prevot et al. 2009). Due to its unique functions during pregnancies, HLA-G may also 
contribute to several tumourigenic processes. In fact, clinically detectable tumours have 
overcome several challenges that resemble the ones present during embryonic 
development. Tumours contain altered genetic material (Schumacher and Schreiber 2015) 
which must be shielded from immunological assault, undergo rapid cell divisions, grow 
invasively and induce neovascularisation. As described in 4.1, HLA-G may contribute to 
all of these processes.  
Our microarray analysis confirmed that high levels of HLA-G are expressed particularly 
by high-grade serous tumours (see Table 2), which account for more than 50% of all 
ovarian cancers (Table 2). Here, significant expression levels were detected in 5 out of 17 
(29%) high-grade tumours (excluding grade 2 tumours due to unclear high/low status). 
However, only four 0.6 µm cores from each tumour were analysed here. When larger 
fractions of primary tumours were screened for HLA-G expression on individual 
sections, expression levels within one tumour were frequently very heterogeneous, and 
HLA-G was often detected only in distinct parts of the tumour. Thus, the frequency of 
HLA-G positive tumours may be underestimated when tumours are assessed only by 
tissue microarrays. In line with this, HLA-G was detected in 7 out of 9 (78%) individual 
sections from high-grade serous tumours. Furthermore, HLA-G was detected in lymph 
nodes of 9 out of 9 patients (100%).  
Tissue microarrays nevertheless remain very efficient tools for initial screenings of large 
amounts of samples. Overall, a trend towards higher HLA-G expression levels in grade 3 
as opposed to grade 1 tumours was observed (see Figure 12). However, this trend did not 
reach statistical significance, which may be ascribed to the limited number of samples. 
Furthermore, HLA-G expression did not significantly correlate with tumour stage or 
patient age (see Figure 12). To our knowledge, the presented tissue microarray screening 
has resulted in the first description of HLA-G expression in mucinous or endometrioid 
ovarian carcinomas. Nonetheless, these findings should be confirmed in further studies. 
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Although an overwhelming amount of evidence suggests that HLA-G is an 
immunosuppressive molecule and may promote tumour growth, patients with high-grade 
ovarian carcinomas that express HLA-G were reported to have a better clinical prognosis 
as compared to patients with HLA-G negative high-grade tumours (Rutten, Dijk et al. 
2014).  
One aim of this thesis was to investigate whether two immunologically distinct subgroups 
as suggested by Gajewski et al. (Gajewski, Schreiber et al. 2013) may exist in ovarian 
carcinoma. This may in fact be the case, as almost all ovarian carcinomas in which HLA-
G is transcribed also transcribed genes coding for classical MHC molecules or proteins 
involved in antigen processing, such as TAP1 (see Table 4). This may be due to the fact 
that all these genes are encoded in the MHC region on chromosome 6. In addition, 
expression of HLA-G can be induced in response to inflammatory cytokines (Wiendl, 
Mitsdoerffer et al. 2002). Thus, some ovarian carcinomas may escape from 
immunosurveillance by compensating for the presentation of tumour antigens on MHC 
class Ia through the expression of immunosuppressive MHC class Ib molecules including 
HLA-G, while others escape from adaptive immune responses because the MHC locus is 
silenced completely. A link between immune cell infiltration and expression of non-
classical MHC molecules has also been shown for HLA-E in glioma (Mittelbronn et al. 
2007). 
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4.3 Induction of HLA-G in immune cells 
We and others have observed heterogeneous HLA-G expression in primary high-grade 
ovarian carcinomas. When larger tumour sections where screened for HLA-G expression, 
we did not detect any HLA-G in 2 out 9 tumours, and 1 only expressed low levels 
(expression score 2). In contrast, high levels of HLA-G (expression score 6 or higher) 
were detected on histiocytes in at least 1 regional lymph node from each patient (see 
Table 3). Histiocytes are extravascular cells of the monocytic line, such as tissue 
macrophages. Within lymph nodes, dendritic cells are the major subpopulation of 
histiocytes. To our knowledge, HLA-G has not previously been detected in local lymph 
nodes in ovarian cancer. However, dendritic cells in regional lymph nodes play a crucial 
role in tumour immunosurveillance (Strioga et al. 2013) and have been successfully used 
in cancer vaccination approaches (Palucka and Banchereau 2012). Dendritic cells take up 
tumour antigens and present them to T cells in regional lymph nodes, thereby priming 
adaptive anti-tumour immune responses. In fact, individual dendritic cells have been 
shown to interact with up to 5000 T cells per hour (Miller et al. 2004). Thus, cancer cells 
often inactivate dendritic cells to interfere with immunosurveillance (Vicari et al. 2002).  
In the context of HLA-G, recent reports have suggested that monocyte-derived dendritic 
cells that are cultured with IL-4, IL-10 and GM-CSF (DC-10) express both high levels of 
ILT4 and HLA-G (Amodio et al. 2013, Gregori, Tomasoni et al. 2010). DC-10 also 
secrete IL-10, are tolerogenic in an ILT4/HLA-G-dependent manner and induce 
regulatory CD8+ T cells (Tr1 cells) (Amodio et al. 2015, Gregori, Tomasoni et al. 2010). 
DC-10 and HLA-G+ CD4+ cells have also been detected in the decidua during pregnancy 
(Amodio, Mugione et al. 2013). Furthermore, IL-10 has been reported to induce HLA-G 
expression in monocytes (Moreau, Adrian-Cabestre et al. 1999) and to be present in high 
concentrations in ascites from ovarian cancer patients (Gotlieb, Abrams et al. 1992). 
Thus, we set out to investigate if IL-10 and possibly also IL-4 induce HLA-G expression 
in monocytic cells. First, IL-4 and IL-10 concentrations in benign and ovarian cancer 
ascites samples were quantified by ELISA. Both cytokines were detectable in partially 
very high concentrations particularly in ascites samples from ovarian cancer patients (see 
Figure 19). In accordance with published protocols (Gregori, Tomasoni et al. 2010), 
adherence enriched monocytes were used initially. These monocytes were matured for 5 
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days in complete RPMI1640 5% hAB serum before IL-4, IL-10 or both cytokines were 
added for 48h. In this setting, we have observed robust HLA-G inductions in numerous 
independent experiments both on protein (see Figure 20) and on mRNA level (data not 
shown). However, when monocytes where purified with anti-CD14 beads, no basal 
expression or induction in response to IL-4 or IL-10 was observed. In contrast, IL-4 and 
IL-10 induced HLA-G expression in the CD14- fraction (PBL). These findings were 
confirmed on mRNA level, where HLA-G was significantly upregulated in T cells (see 
Figure 21). HLA-G mRNA expression in monocytes and NK cells was very low, but also 
significantly increased in response to IL-4. However, these bead-purified monocytes were 
only 90% to 95% pure, and it is thus likely that the detected HLA-G mRNA was derived 
from few contaminating T cells.  
Similar reasons may have led to the description of HLA-G expression in monocytes or 
dendritic cells. Here, purity analyses revealed that only 25% to 60% of adherence-
enriched cells were actually CD14+ monocytes (Figure 20). Thus, all evidence suggests 
that HLA-G expression in adherence-enriched cells may be due to contaminating PBL. 
Of note, as discussed below, monocytes or dendritic cells may still acquire HLA-G from 
other immune cells. Overall, the HLA-G mRNA to 18S rRNA ratio in untreated T cells 
was more than 100 fold lower as in Jeg-3 cells (see Figure 20). On protein level, this was 
not systematically investigated, however, 1 µg of Jeg-3 lysate usually resulted in stronger 
signals than 20 µg of lysate from 2 x 106 immune cells (not shown).  
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4.4 Transfer of soluble HLA-G to dendritic cells 
As HLA-G was not inducible in monocytes or DC-10, we speculated that dendritic cells 
might take up tumour-derived soluble HLA-G. Monocytic cells had been shown to bind 
HLA-G tetramers through HLA-G receptors such as ILT4 (Biancotto, Wank et al. 2013, 
Kleiner, Marcuzzi et al. 2013). In accordance with the literature (Singer, Rebmann et al. 
2003), we detected high levels of soluble HLA-G in ascites samples from ovarian 
carcinoma patients (see Figure 22). Then, we quantified ILT4 surface expression on 
different immune cells. As reported by others (Gregori, Tomasoni et al. 2010, LeMaoult 
et al. 2005, Shiroishi, Tsumoto et al. 2003), ILT4 was detectable on dendritic cells that 
had been cultured for 7 days with IL-4 and GM-CSF (also often referred to as immature 
dendritic cells or iDC) and expressed at even higher levels on DC-10 (see Figure 23). In 
order to test whether DC-10 absorb soluble HLA-G from the microenvironment, DC-10 
were incubated with supernatants from a cell line transfected with a plasmid coding for a 
single chain HLA-G5 construct. Here, HLA-G5 and β2-microglobulin are linked with a 
flexible peptide linker. Thus, the construct has a molecular weight of about 50 kDa and is 
thereby distinguishable from all natural isoforms of HLA-G by Western Blotting. We 
found that DC-10 quickly and efficiently bind high amounts of scHLA-G-5 both at 4°C 
or at 37°C. In contrast, no HLA-G was detectable on DC-10 that were incubated with 
supernatant from mock transfected cells (see Figure 24). Cells were washed three times in 
order to ensure that no unbound HLA-G from the supernatant had been carried over into 
the protein lysates. Here, 2.5 x 105 DC-10 cells were sufficient to demonstrate HLA-G 
transfer by Western Blotting. Binding of HLA-G by DC-10 was clearly reduced in 
presence of antibodies that block HLA-G, ILT2 or ILT4 (see Figure 25), which highlights 
the importance of these receptors during HLA-G transfer. At this point, it is unclear why 
blocking of the ILT2 receptor also decreased binding of soluble HLA-G. Both receptors 
could be involved in the transfer process in a cooperative manner. In some lymph nodes 
with very intense HLA-G staining, it was difficult to determine if other immune cells had 
also taken up HLA-G (see Figure 16). Thus, it cannot be excluded that sHLA-G may to 
some extent bind to ILT2. Alternatively, blocking one receptor with a relatively large 
antibody could also interfere with HLA-G binding to the other type of receptor for steric 
reasons if both are localized in close proximity. Furthermore, as both receptors are 
closely related, the blocking antibodies may cross-react to a certain extent.  
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4.5 Soluble HLA-G increases the immunosuppressive capacity of DC-10 
The next obvious step was to investigate which effects the transfer of HLA-G to dendritic 
cells may have in local lymph nodes. It is known that a high frequency of tumour 
infiltrating CD8+ T cells and particularly a high CD8+ to CD4+ Treg ratio are associated 
with favourable clinical outcomes in ovarian cancer (Sato, Olson et al. 2005). We have 
shown that DC-10 which are loaded with soluble HLA-G (DC-10scHLA-G5) efficiently 
induce CD4+FoxP3+ regulatory T cells (see Figure 26). However, in this setting, it was 
not clear whether Treg cells were induced because of effects directly mediated by soluble 
HLA-G on the surface of DC-10 cells, or because of secondary effects such as DC-10 
derived cytokines or surface molecules induced by HLA-G. Thus, in the next set of 
experiments, DC-10scHLA-G5 and DC-10 incubated with control supernatant were fixed in 
1% paraformaldehyde. We have observed that Jeg-3 cells fixed by the same protocol 
inhibit T cell proliferation in a HLA-G dependant manner.  
After several washes, syngeneic PBL stained with cell proliferation dye were added and 
T cell proliferation was induced by PHA. Here, CD8+ T cell proliferation was most 
effectively suppressed by fixed DC-10 loaded with HLA-G in three independent 
experiments (see Figure 27). Again, substantial donor-dependent differences were 
observed.  
4.6  Conclusion 
We have shown that HLA-G is expressed in various subtypes of ovarian cancer, and in 
the majority of high-grade serous tumours. However, HLA-G expressing tumours may 
also frequently express classical HLA molecules while others may escape from 
immunosurveillance by downregulating all MHC molecules. Thus, HLA-G expression is 
not necessarily associated with a poor clinical prognosis. HLA-G was also detectable on 
dendritic cells in lymph nodes from all assessed patients. Our experiments suggest that 
dendritic cells may not express HLA-G, but are capable of binding tumour-derived 
soluble HLA-G. Such HLA-G loaded dendritic cells are highly immunosuppressive. 
Thus, soluble HLA-G may enable serous ovarian carcinomas to remotely inhibit anti-
tumour immune responses in regional lymph nodes (see Figure 28). This novel 
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immunosuppressive mechanism may also protect other solid tumours that secrete HLA-G 
and could play an important role during embryogenesis. 
 
 
Figure 28: Soluble HLA-G may remotely suppress anti-tumour immune responses in regional lymph nodes 
Ovarian carcinomas and other tumours express altered proteins that should in principle initiate anti-tumour 
immune responses. Dendritic cells in regional lymph nodes are, however, critical for priming such a 
response. They may enter malignant tissues and take up tumour antigens before they migrate to lymph 
nodes (not shown). Alternatively, dendritic cells within a lymph node may take up tumour antigens via 
pinocytosis. These antigens are then presented to T cells, which start proliferating if they express cognate T 
cell receptors. Such cytotoxic CD8+ T cells effectively detect and eliminate malignant cells. However, 
dendritic cells also bind tumour-derived soluble HLA-G. In this case, CD8+ T cell proliferation is inhibited 
and regulatory T cells are induced, which may migrate into the tumours and suppress further immune 
responses. This mechanism may have evolved to protect semi-allogeneic embryos from adaptive immune 
responses (see main text for references). 
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Supplements 
Table 5: Characteristics of tissue donors included in the FFPE Norm2 TMA 
Tissue Age Sex 
 
Tissue Age Sex 
breast, epithelium 47 F  liver 76 M 
aorta, smooth muscle 44 M  pancreas 67 F 
heart, myocardium 51 M  lymph node 6 F 
adrenal gland, cortex 51 M  
mucosa assoc. lymph. tissue, 
appendix 66 F 
adrenal gland, medulla 51 F  spleen 70 M 
parathyroid (hyperplastic) 45 F  thymus 48 F 
thyroid 38 F  cerebral cortex 64 M 
esophagus, squamous mucosa 58 M  white matter (subcortical) 33 F 
gastric mucosa, antral 59 F  peripheral nerve 50 F 
gastric mucosa, oxyntic 53 F  salivary gland (parotid) 40 M 
small intestine, mucosa 85 F  tonsil, squamous epithelium 24 M 
colon, mucosa 66 M  amniotic membrane 21 F 
anus, mucosa 39 F  placenta, villi 24 F 
ectocervix 43 F  alveoli 43 M 
endocervix 43 F  bronchus, epithelium 52 M 
endometrium, secretory 45 F  skin, squamous epithelium 61 F 
fallopian tube 49 F  cartilage, articular 43 M 
ovary, oocytes 54 F  skeletal muscle 48 F 
ovary, corpus luteum 49 F  smooth muscle, intestine 82 F 
ovary, mesothelium 44 F  smooth muscle, uterus 56 F 
seminiferous tubules 36 M  synovium 30 F 
epididymis 66 M  kidney, cortex 47 F 
seminal vessicle 44 M  kidney, medulla 61 M 
prostate 52 M  bladder, transitional epithelium 49 M 
gallbladder 56 M     
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Table 6: Manufacturing company locations 
Company Location 
Applied Biosystems see Life Technologies 
BD Pharmingen/BD Biosciences see Becton, Dickinson and Company 
Beckman Coulter Brea, CA, USA 
Becton, Dickinson and Company Franklin Lakes, NJ, USA 
Bio-Rad Laboratories, Inc. Hercules, CA, USA 
BioLegend San Diego, CA, USA 
Carl Roth GmbH & Co. KG Karlsruhe, Germany 
Cell Signaling Technologies Danvers, MA, USA 
Dako, Agilent Technologies Santa Clara, CA, USA 
Eastman Kodak Rochester, NY, USA 
eBioscience San Diego, CA, USA 
ExBio ExBio, Praha, Czech Republic 
ImmunoTools  Friesoythe, Germany 
Leica Camera AG Wetzlar, Germany 
Life Technologies Carlsbad, CA, USA 
Miltenyi Biotec GmbH Bergisch Gladbach, Germany 
Molecular Probes see Thermo Fisher 
Sigma-Aldrich St. Louis, MO, USA 
Southern Biotech Birmingham, AL, USA 
Tecan Trading AG Männedorf, Switzerland 
Thermo Fisher Scientific Inc. Waltham, MA, USA 
Leica Biosystems Newcastle Ltd Newcastle Upon Tyne, UK 
 
Table 7: Alignment Qa-2 (H-2Q7) and Blastocyst MHC (H-2Bl) 
 
H-2Q7 RTDPPKAHVTHHPRSYGAVTLRCWALGFYPADITLTWQLNGEELTQDMEL  
      ||||||||||.|||..|.||||||||||||||||||||||||||||||||  
H-2Bl RTDPPKAHVTRHPRPAGDVTLRCWALGFYPADITLTWQLNGEELTQDMEL  
 
H-2Q7 VETRPAGDGTFQKWASVVVPLGKEQNYTCHVNHEGLPEPLTLRW  
      |||||||||||||||:|||||||||||||.|:||||||||||||  
H-2Bl VETRPAGDGTFQKWAAVVVPLGKEQNYTCRVHHEGLPEPLTLRW     
 
Alpha 3 domains of Qa-2 and Blastocyst MHC were aligned using ClustalW. 
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